| Drug |
rituximab |
594 |
2010 |
| Drug |
cyclophosphamide |
472 |
2020 |
| Other |
laboratory biomarker analysis |
251 |
2010 |
| Drug |
etoposide |
242 |
2010 |
| Drug |
prednisone |
208 |
2020 |
| Biological |
filgrastim |
151 |
2014 |
| Drug |
cytarabine |
148 |
2014 |
| Drug |
lenalidomide |
138 |
2014 |
| Drug |
methotrexate |
138 |
2014 |
| Drug |
vincristine sulfate |
134 |
2018 |
| Drug |
doxorubicin hydrochloride |
133 |
2014 |
| Radiation |
radiotherapy |
131 |
2014 |
| Procedure |
peripheral blood stem cell transplantation |
130 |
2016 |
| Drug |
dexamethasone |
124 |
2019 |
| Drug |
vincristine |
117 |
2010 |
| Drug |
doxorubicin |
115 |
2014 |
| Other |
pharmacological study |
107 |
2014 |
| Drug |
ibrutinib |
105 |
2018 |
| Drug |
fludarabine phosphate |
102 |
2017 |
| Drug |
melphalan |
101 |
2011 |
| Drug |
fludarabine |
97 |
2015 |
| Drug |
bendamustine |
89 |
2014 |
| Drug |
bortezomib |
83 |
2010 |
| Drug |
brentuximab vedotin |
80 |
2014 |
| Drug |
busulfan |
78 |
2010 |
| Drug |
mycophenolate mofetil |
75 |
2018 |
| Drug |
ifosfamide |
70 |
2014 |
| Biological |
pembrolizumab |
66 |
2015 |
| Drug |
cyclosporine |
63 |
2010 |
| Drug |
gemcitabine |
62 |
2010 |
| Drug |
tacrolimus |
62 |
2018 |
| Drug |
carmustine |
61 |
2014 |
| Biological |
nivolumab |
59 |
2018 |
| Drug |
obinutuzumab |
54 |
2014 |
| Radiation |
total-body irradiation |
52 |
2017 |
| Drug |
carboplatin |
51 |
2010 |
| Procedure |
allogeneic hematopoietic stem cell transplantation |
48 |
2018 |
| placebo |
placebo |
47 |
2017 |
| Biological |
anti-thymocyte globulin |
41 |
2008 |
| Drug |
venetoclax |
41 |
2018 |
| Procedure |
allogeneic bone marrow transplantation |
40 |
2010 |
| Drug |
g-csf |
40 |
2018 |
| Drug |
leucovorin calcium |
40 |
2010 |
| Drug |
ofatumumab |
40 |
2010 |
| Drug |
dacarbazine |
39 |
2014 |
| Drug |
cisplatin |
38 |
2016 |
| Biological |
pegfilgrastim |
36 |
2019 |
| Other |
quality-of-life assessment |
36 |
2011 |
| Drug |
vorinostat |
36 |
2009 |
| Drug |
methylprednisolone |
35 |
2010 |
| Drug |
romidepsin |
34 |
2014 |
| Drug |
vinblastine |
34 |
2014 |
| Drug |
prednisolone |
30 |
2009 |
| Biological |
sargramostim |
29 |
2015 |
| Procedure |
autologous hematopoietic stem cell transplantation |
28 |
2011 |
| Drug |
gemcitabine hydrochloride |
25 |
2009 |
| Drug |
thiotepa |
25 |
2014 |
| Biological |
aldesleukin |
24 |
2012 |
| Procedure |
bone marrow ablation with stem cell support |
24 |
2005 |
| Drug |
oxaliplatin |
24 |
2010 |
| Other |
questionnaire administration |
24 |
2018 |
| Drug |
bendamustine hydrochloride |
23 |
2010 |
| Drug |
pegaspargase |
23 |
2018 |
| Procedure |
umbilical cord blood transplantation |
22 |
2012 |
| Biological |
alemtuzumab |
21 |
2009 |
| Biological |
bleomycin sulfate |
21 |
2014 |
| Drug |
clofarabine |
21 |
2013 |
| Biological |
therapeutic allogeneic lymphocytes |
21 |
2013 |
| Drug |
bleomycin |
20 |
2014 |
| Drug |
mesna |
20 |
2014 |
| Drug |
sirolimus |
20 |
2009 |
| Drug |
everolimus |
19 |
2014 |
| Drug |
mercaptopurine |
19 |
2010 |
| Procedure |
autologous bone marrow transplantation |
18 |
2015 |
| Drug |
r-chop |
18 |
2017 |
| Drug |
chop |
17 |
2019 |
| Biological |
tositumomab |
17 |
2007 |
| Radiation |
yttrium y 90 ibritumomab tiuxetan |
17 |
2012 |
| Drug |
chidamide |
16 |
2018 |
| Drug |
chop regimen |
16 |
2009 |
| Procedure |
nonmyeloablative allogeneic hematopoietic stem cell transplantation |
16 |
2009 |
| Drug |
temsirolimus |
16 |
2010 |
| Drug |
acalabrutinib |
15 |
2014 |
| Drug |
plerixafor |
15 |
2010 |
| Drug |
procarbazine hydrochloride |
15 |
2011 |
| Drug |
decitabine |
14 |
2018 |
| Biological |
ipilimumab |
14 |
2014 |
| Drug |
mitoxantrone hydrochloride |
14 |
2011 |
| Drug |
paclitaxel |
14 |
2009 |
| Drug |
alisertib |
13 |
2014 |
| Drug |
blinatumomab |
13 |
2017 |
| Drug |
carfilzomib |
13 |
2010 |
| Drug |
copanlisib |
13 |
2019 |
| Drug |
etoposide phosphate |
13 |
2018 |
| Other |
flow cytometry |
13 |
2010 |
| Drug |
idelalisib |
13 |
2014 |
| Drug |
vinblastine sulfate |
13 |
2019 |
| Drug |
atezolizumab |
12 |
2014 |
| Radiation |
iodine i 131 tositumomab |
12 |
2005 |
| Procedure |
leukapheresis |
12 |
2009 |
| Drug |
panobinostat |
12 |
2009 |
| Radiation |
total body irradiation |
12 |
2018 |
| Drug |
velcade |
12 |
2020 |
| Drug |
pegylated liposomal doxorubicin hydrochloride |
11 |
2006 |
| Drug |
pentostatin |
11 |
2009 |
| Drug |
polatuzumab vedotin |
11 |
2016 |
| Drug |
therapeutic hydrocortisone |
11 |
2010 |
| Drug |
thioguanine |
11 |
2017 |
| Biological |
bevacizumab |
10 |
2007 |
| Drug |
cladribine |
10 |
2009 |
| Drug |
crizotinib |
10 |
2020 |
| Other |
immunohistochemistry staining method |
10 |
2011 |
| Drug |
mitoxantrone |
10 |
2013 |
| Drug |
pralatrexate |
10 |
2018 |
| Biological |
recombinant interferon alfa |
10 |
1999 |
| Drug |
tazemetostat |
10 |
2014 |
| Drug |
thalidomide |
10 |
2014 |
| Drug |
tocilizumab |
10 |
2018 |
| Drug |
zanubrutinib |
10 |
2019 |
| Drug |
adriamycin |
9 |
2018 |
| Drug |
asparaginase |
9 |
2010 |
| Drug |
avelumab |
9 |
2018 |
| Biological |
axicabtagene ciloleucel |
9 |
2015 |
| Drug |
bryostatin 1 |
9 |
1999 |
| Drug |
chemotherapy |
9 |
2017 |
| Drug |
chlorambucil |
9 |
2014 |
| Drug |
daunorubicin hydrochloride |
9 |
2014 |
| Drug |
durvalumab |
9 |
2017 |
| Drug |
enzastaurin |
9 |
2011 |
| Drug |
ixazomib |
9 |
2017 |
| Drug |
leucovorin |
9 |
2009 |
| Drug |
nelarabine |
9 |
2017 |
| Biological |
tositumomab/iodine i 131 tositumomab |
9 |
2009 |
| Drug |
vindesine |
9 |
2016 |
| Drug |
allopurinol |
8 |
2016 |
| Procedure |
autologous stem cell transplantation |
8 |
2014 |
| Drug |
bcnu |
8 |
2010 |
| Procedure |
biopsy |
8 |
2017 |
| Drug |
dasatinib |
8 |
2020 |
| Drug |
duvelisib |
8 |
2019 |
| Drug |
epirubicin |
8 |
2020 |
| Drug |
epoch |
8 |
2011 |
| Drug |
gm-csf |
8 |
2000 |
| Procedure |
in vitro-treated bone marrow transplantation |
8 |
2005 |
| Drug |
kg |
8 |
2014 |
| Biological |
kw-0761 |
8 |
2010 |
| Drug |
parsaclisib |
8 |
2017 |
| Genetic |
polymerase chain reaction |
8 |
2011 |
| Procedure |
positron emission tomography |
8 |
2011 |
| Drug |
rituxan] |
8 |
2013 |
| Drug |
rituximab [mabthera |
8 |
2013 |
| Drug |
rituximab [mabthera/rituxan] |
8 |
2013 |
| Drug |
tgr-1202 |
8 |
2014 |
| Drug |
topotecan hydrochloride |
8 |
2012 |
| Drug |
vinorelbine |
8 |
2018 |
| Drug |
vinorelbine tartrate |
8 |
2007 |
| Drug |
zevalin |
8 |
2009 |
| Drug |
azacitidine |
7 |
2013 |
| Drug |
belinostat |
7 |
2016 |
| Procedure |
care |
7 |
2008 |
| Other |
educational intervention |
7 |
2017 |
| Dietary Supplement |
folic acid |
7 |
2014 |
| Drug |
ibritumomab tiuxetan |
7 |
2013 |
| Drug |
idarubicin |
7 |
2018 |
| Drug |
il-2 |
7 |
2009 |
| Drug |
irinotecan hydrochloride |
7 |
2017 |
| Drug |
palbociclib |
7 |
2018 |
| Procedure |
psychosocial assessment |
7 |
2008 |
| Procedure |
psychosocial assessment/care |
7 |
2008 |
| Drug |
rituxan |
7 |
2014 |
| Drug |
ruxolitinib |
7 |
2016 |
| Radiation |
total body irradiation (tbi) |
7 |
2011 |
| Dietary Supplement |
vitamin b12 |
7 |
2014 |
| Procedure |
allogeneic stem cell transplantation |
6 |
2014 |
| Drug |
alvocidib |
6 |
1999 |
| Drug |
ara-c |
6 |
2012 |
| Procedure |
autologous stem cell transplant |
6 |
2010 |
| Drug |
beam |
6 |
2014 |
| Drug |
bexarotene |
6 |
2012 |
| Drug |
cc-122 |
6 |
2014 |
| Drug |
daratumumab |
6 |
2017 |
| Drug |
darbepoetin alfa |
6 |
2016 |
| Drug |
daunorubicin |
6 |
2017 |
| Drug |
dhap |
6 |
2012 |
| Biological |
graft-versus-tumor induction therapy |
6 |
2007 |
| Procedure |
in vitro-treated peripheral blood stem cell transplantation |
6 |
1999 |
| Drug |
inotuzumab ozogamicin |
6 |
2019 |
| Drug |
l-asparaginase |
6 |
2009 |
| Biological |
palifermin |
6 |
2010 |
| Drug |
pci-32765 |
6 |
2009 |
| Other |
pharmacogenomic studies |
6 |
2011 |
| Drug |
pralatrexate injection |
6 |
2010 |
| Drug |
procarbazine |
6 |
2018 |
| Biological |
recombinant interleukin-12 |
6 |
1999 |
| Drug |
selinexor |
6 |
2017 |
| Drug |
sintilimab |
6 |
2020 |
| Procedure |
stem cell infusion |
6 |
2012 |
| Procedure |
stem cell transplant |
6 |
2014 |
| Drug |
thymoglobulin |
6 |
2009 |
| Biological |
tisagenlecleucel |
6 |
2018 |
| Drug |
abexinostat |
5 |
2018 |
| Drug |
abt-199 |
5 |
2012 |
| Drug |
abvd |
5 |
2017 |
| Device |
clinimacs |
5 |
2019 |
| Procedure |
computed tomography |
5 |
2009 |
| Diagnostic Test |
ct-scan |
5 |
2018 |
| Biological |
denileukin diftitox |
5 |
2007 |
| Drug |
docetaxel |
5 |
2016 |
| Drug |
g-csf/plerixafor |
5 |
2007 |
| Drug |
glofitamab |
5 |
2018 |
| Drug |
hydrocortisone |
5 |
2014 |
| Drug |
lomustine |
5 |
2018 |
| Radiation |
low-let cobalt-60 gamma ray therapy |
5 |
1999 |
| Radiation |
low-let photon therapy |
5 |
1999 |
| Drug |
observation |
5 |
2013 |
| Other |
pharmacokinetic study |
5 |
2018 |
| Genetic |
polymorphism analysis |
5 |
2011 |
| Drug |
rifampin |
5 |
2014 |
| Procedure |
stem cell transplantation |
5 |
2016 |
| Biological |
therapeutic autologous lymphocytes |
5 |
2008 |
| Drug |
ublituximab |
5 |
2019 |
| Drug |
veliparib |
5 |
2011 |
| Genetic |
western blotting |
5 |
2008 |
| Drug |
zidovudine |
5 |
2016 |
| Biological |
NA |
4 |
2019 |
| Drug |
7-hydroxystaurosporine |
4 |
2001 |
| Drug |
afm13 |
4 |
2017 |
| Drug |
akt inhibitor mk2206 |
4 |
2011 |
| Biological |
apolizumab |
4 |
2004 |
| Drug |
arsenic trioxide |
4 |
2005 |
| Drug |
atg |
4 |
2016 |
| Drug |
bendamustine/rituximab |
4 |
2011 |
| Drug |
camrelizumab |
4 |
2020 |
| Biological |
cd19 |
4 |
2018 |
| Drug |
clarithromycin |
4 |
2011 |
| Drug |
copanlisib (bay80-6946) |
4 |
2014 |
| Other |
correlative studies |
4 |
2013 |
| Drug |
cyclophosphamide (cy) |
4 |
2018 |
| Drug |
dexrazoxane hydrochloride |
4 |
2010 |
| Genetic |
dna analysis |
4 |
2011 |
| Drug |
entinostat |
4 |
2017 |
| Biological |
epoetin alfa |
4 |
2006 |
| Biological |
epratuzumab |
4 |
2007 |
| Drug |
etoposide (vp-16) |
4 |
2018 |
| Radiation |
fludeoxyglucose f-18 |
4 |
2010 |
| Radiation |
fludeoxyglucose f 18 |
4 |
2011 |
| Genetic |
fluorescence in situ hybridization |
4 |
2010 |
| Drug |
fluorouracil |
4 |
1999 |
| Drug |
ganciclovir |
4 |
2005 |
| Genetic |
gene expression analysis |
4 |
2010 |
| Procedure |
hematopoietic cell transplantation |
4 |
2017 |
| Drug |
ibritumomab tiuxetan (zevalin) |
4 |
2010 |
| Drug |
icp-022 |
4 |
2020 |
| Radiation |
indium in 111 ibritumomab tiuxetan |
4 |
2007 |
| Drug |
inotuzumab ozogamicin (cmc-544) |
4 |
2009 |
| Drug |
irinotecan |
4 |
2018 |
| Drug |
jcar017 |
4 |
2018 |
| Genetic |
microarray analysis |
4 |
2008 |
| Drug |
mosunetuzumab |
4 |
2018 |
| Drug |
mycophenolate mofetil (mmf) |
4 |
2018 |
| Drug |
olaparib |
4 |
2017 |
| Drug |
omeprazole |
4 |
2016 |
| Drug |
ondansetron |
4 |
2008 |
| Drug |
ontak |
4 |
2006 |
| Drug |
peg-asparaginase |
4 |
2017 |
| Drug |
pemetrexed |
4 |
2016 |
| Device |
pet |
4 |
2018 |
| Drug |
pixantrone |
4 |
2018 |
| Drug |
rasburicase |
4 |
2007 |
| Drug |
sar3419 |
4 |
2011 |
| Other |
standard care |
4 |
2018 |
| Drug |
sunitinib malate |
4 |
2015 |
| Drug |
tak-659 |
4 |
2017 |
| Drug |
tanespimycin |
4 |
2005 |
| Radiation |
tbi |
4 |
2019 |
| Drug |
temozolomide |
4 |
2018 |
| Drug |
tipifarnib |
4 |
2017 |
| Radiation |
total nodal irradiation |
4 |
2015 |
| Drug |
trametinib dimethyl sulfoxide |
4 |
2020 |
| Drug |
umbralisib |
4 |
2018 |
| Biological |
utomilumab |
4 |
2018 |
| Biological |
ziv-aflibercept |
4 |
2004 |
| Drug |
abvd regimen |
3 |
2009 |
| Drug |
amifostine trihydrate |
3 |
1999 |
| Procedure |
apheresis |
3 |
2014 |
| Drug |
aprepitant |
3 |
2008 |
| Procedure |
assessment of therapy complications |
3 |
2008 |
| Procedure |
autologous-autologous tandem hematopoietic stem cell transplantation |
3 |
2005 |
| Drug |
azacytidine |
3 |
2009 |
| Drug |
betalutin |
3 |
2019 |
| Drug |
bgb-3111 |
3 |
2018 |
| Drug |
binimetinib |
3 |
2020 |
| Procedure |
bone marrow aspiration |
3 |
2018 |
| Drug |
buparlisib |
3 |
2016 |
| Drug |
busulfan (bu) |
3 |
2018 |
| Biological |
cart-19 |
3 |
2012 |
| Drug |
cc-292 |
3 |
2014 |
| Biological |
cd19-tricar-t |
3 |
2018 |
| Biological |
chimeric antigen receptor t-cell therapy |
3 |
2019 |
| Dietary Supplement |
cholecalciferol |
3 |
2014 |
| Drug |
cobomarsen |
3 |
2019 |
| Radiation |
consolidation involved-field radiotherapy (ifrt) |
3 |
2015 |
| Radiation |
consolidation involved-site radiotherapy (isrt) |
3 |
2015 |
| Drug |
copanlisib (aliqopa, bay80-6946) |
3 |
2015 |
| Drug |
copanlisib hydrochloride |
3 |
2018 |
| Drug |
cytoxan |
3 |
2019 |
| Biological |
donor lymphocytes |
3 |
2007 |
| Procedure |
double-unit umbilical cord blood transplantation |
3 |
2010 |
| Drug |
doxil |
3 |
2013 |
| Drug |
dtrmwxhs-12 |
3 |
2019 |
| Other |
enzyme-linked immunosorbent assay |
3 |
2011 |
| Drug |
erdafitinib |
3 |
2017 |
| Drug |
fenretinide |
3 |
2010 |
| Drug |
gallium nitrate |
3 |
1999 |
| Drug |
granulocyte-colony stimulating factor (g-csf) |
3 |
2010 |
| Biological |
gvhd prophylaxis |
3 |
2009 |
| Drug |
hbi-8000 |
3 |
2016 |
| Drug |
humax-cd4 |
3 |
2009 |
| Drug |
imatinib mesylate |
3 |
2017 |
| Other |
immunoenzyme technique |
3 |
2010 |
| Other |
immunologic technique |
3 |
2006 |
| Drug |
interleukin-2 |
3 |
2018 |
| Drug |
ixabepilone |
3 |
2003 |
| Drug |
ixazomib citrate |
3 |
2014 |
| Drug |
ketoconazole |
3 |
2011 |
| Drug |
laromustine |
3 |
2006 |
| Drug |
larotrectinib |
3 |
2017 |
| Drug |
lbh589 |
3 |
2007 |
| Drug |
lenvatinib |
3 |
2015 |
| Drug |
liposomal doxorubicin |
3 |
2018 |
| Drug |
loncastuximab tesirine |
3 |
2018 |
| Radiation |
low-let electron therapy |
3 |
1999 |
| Drug |
m2 |
3 |
2011 |
| Biological |
mabtheraâ® |
3 |
2016 |
| Procedure |
management of therapy complications |
3 |
2008 |
| Drug |
me-401 |
3 |
2016 |
| Drug |
mmf |
3 |
2009 |
| Drug |
motexafin gadolinium |
3 |
2006 |
| Biological |
multi-peptide cmv-modified vaccinia ankara vaccine |
3 |
2018 |
| Drug |
nab-paclitaxel |
3 |
2015 |
| Biological |
oblimersen sodium |
3 |
2004 |
| Drug |
oral azacitidine |
3 |
2018 |
| Drug |
pci-32765 (ibrutinib) |
3 |
2013 |
| Drug |
pdr001 |
3 |
2017 |
| Drug |
peg-rhg-csf |
3 |
2019 |
| Drug |
perifosine |
3 |
2009 |
| Procedure |
peripheral blood stem cell transplantation (pbsct) |
3 |
2011 |
| Biological |
pet scan |
3 |
2009 |
| Drug |
pf-3512676 |
3 |
2009 |
| Other |
pharmacogenomic study |
3 |
2015 |
| Drug |
pi3k-beta inhibitor gsk2636771 |
3 |
2020 |
| Biological |
pneumococcal 13-valent conjugate vaccine |
3 |
2014 |
| Drug |
pnt2258 |
3 |
2010 |
| Drug |
pomalidomide |
3 |
2019 |
| Other |
questionnaire |
3 |
2008 |
| Drug |
r-dhap |
3 |
2013 |
| Drug |
rad001 |
3 |
2008 |
| Drug |
rituximab 375 mg |
3 |
2011 |
| Genetic |
rna analysis |
3 |
2011 |
| Drug |
sd-101 |
3 |
2014 |
| Drug |
sgn-40 |
3 |
2008 |
| Drug |
shr-1210 |
3 |
2017 |
| Drug |
sorafenib |
3 |
2012 |
| Drug |
sorafenib tosylate |
3 |
2006 |
| Drug |
sp-02l (darinaparsin for injection) |
3 |
2015 |
| Procedure |
standard follow-up care |
3 |
2010 |
| Drug |
stem cells |
3 |
2012 |
| Drug |
syb l-0501 |
3 |
2010 |
| Procedure |
syngeneic bone marrow transplantation |
3 |
1999 |
| Drug |
teniposide |
3 |
2012 |
| Drug |
toripalimab |
3 |
2019 |
| Drug |
ulixertinib |
3 |
2018 |
| Drug |
valproic acid |
3 |
2019 |
| Biological |
veltuzumab |
3 |
2009 |
| Drug |
vemurafenib |
3 |
2016 |
| Dietary Supplement |
vitamin d |
3 |
2017 |
| Drug |
vp16 |
3 |
2016 |
| Radiation |
yttrium y-90 ibritumomab tiuxetan |
3 |
2014 |
| Drug |
(pn-152,243) |
2 |
2002 |
| Drug |
6-mercaptopurine |
2 |
2017 |
| Drug |
90y ibritumomab tiuxetan |
2 |
2011 |
| Procedure |
ablative allogeneic hematopoietic cell transplantation |
2 |
2005 |
| Drug |
abt-888 |
2 |
2011 |
| Drug |
acetaminophen |
2 |
2007 |
| Drug |
adavosertib |
2 |
2020 |
| Drug |
adg106 |
2 |
2018 |
| Procedure |
adjuvant therapy |
2 |
2005 |
| Drug |
afatinib dimaleate |
2 |
2020 |
| Drug |
agatolimod sodium |
2 |
2007 |
| Drug |
alectinib |
2 |
2017 |
| Biological |
allo-647 |
2 |
2020 |
| Biological |
allogeneic epstein-barr virus-specific cytotoxic t lymphocytes |
2 |
2000 |
| Procedure |
allogeneic stem cell transplant |
2 |
2010 |
| Drug |
alvespimycin hydrochloride |
2 |
2004 |
| Drug |
alvocidib hydrochloride |
2 |
2004 |
| Biological |
amg 531 |
2 |
2006 |
| Drug |
amifostine |
2 |
2005 |
| Drug |
aminocamptothecin |
2 |
1999 |
| Drug |
amoxicillin |
2 |
1999 |
| Biological |
anakinra |
2 |
2019 |
| Biological |
anti-cd19 |
2 |
2017 |
| Drug |
apatinib |
2 |
2017 |
| Drug |
arac |
2 |
2014 |
| Procedure |
asct |
2 |
2008 |
| Drug |
asparaginase erwinia chrysanthemi |
2 |
2019 |
| Drug |
astx660 |
2 |
2020 |
| Drug |
at-101 |
2 |
2006 |
| Combination Product |
atg-019 |
2 |
2020 |
| Biological |
atlcar.cd30 cells |
2 |
2016 |
| Procedure |
auto-hsct |
2 |
2016 |
| Drug |
auto-sct |
2 |
2018 |
| Biological |
autologous |
2 |
2018 |
| Procedure |
autologous-allogeneic tandem hematopoietic stem cell transplantation |
2 |
2009 |
| Biological |
autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells |
2 |
2013 |
| Biological |
autologous cd19car-cd28-cd3zeta-egfrt-expressing tn |
2 |
2014 |
| Biological |
autologous cd19car-cd28-cd3zeta-egfrt-expressing tn/mem-enriched t-lymphocytes |
2 |
2014 |
| Drug |
autologous hematopoietic stem cell transplant (hsct) |
2 |
2007 |
| Procedure |
autologous stem cell transplantation (asct) |
2 |
2017 |
| Biological |
avastin |
2 |
2013 |
| Drug |
azd5153 |
2 |
2017 |
| Drug |
azd9150 |
2 |
2018 |
| Drug |
becatecarin |
2 |
2000 |
| Drug |
beclomethasone dipropionate |
2 |
2001 |
| Behavioral |
behavioral techniques |
2 |
2016 |
| Drug |
bendamustine hcl |
2 |
2008 |
| Drug |
bexxar |
2 |
2007 |
| Drug |
bi 836826 |
2 |
2015 |
| Biological |
bind19 |
2 |
2017 |
| Drug |
bl-8040 |
2 |
2015 |
| Procedure |
blood |
2 |
2018 |
| Other |
blood sample |
2 |
2019 |
| Biological |
bone marrow transplant |
2 |
2011 |
| Drug |
bortezomib (velcade) |
2 |
2010 |
| Drug |
bortezomib / rituximab |
2 |
2006 |
| Drug |
brentuximab vedotin (sgn-35) |
2 |
2012 |
| Drug |
brigatinib |
2 |
2018 |
| Biological |
bz019 |
2 |
2020 |
| Biological |
campath |
2 |
2009 |
| Drug |
campath-1h |
2 |
2007 |
| Drug |
capecitabine |
2 |
2010 |
| Drug |
capivasertib |
2 |
2020 |
| Biological |
car-t |
2 |
2017 |
| Biological |
car-t cells |
2 |
2018 |
| Drug |
cc-223 |
2 |
2014 |
| Biological |
cd19-tricar-t/silk |
2 |
2018 |
| Biological |
cd19 car-t cells |
2 |
2020 |
| Biological |
cd19 car t cells |
2 |
2017 |
| Biological |
cd8 |
2 |
2017 |
| Drug |
cdx-301 |
2 |
2017 |
| Drug |
chop/rituximab |
2 |
2007 |
| Drug |
cilengitide |
2 |
2000 |
| Drug |
cisplatinum |
2 |
2016 |
| Diagnostic Test |
clinical |
2 |
2019 |
| Drug |
conditioning chemotherapy |
2 |
2015 |
| Procedure |
conventional surgery |
2 |
2001 |
| Drug |
copanlisib (bay 80-6946) |
2 |
2015 |
| Procedure |
cord blood infusion |
2 |
2011 |
| Biological |
cs1001 |
2 |
2018 |
| Drug |
ct-011 |
2 |
2009 |
| Biological |
ct-p10 |
2 |
2014 |
| Procedure |
ct scan |
2 |
2011 |
| Drug |
cudc-907 |
2 |
2016 |
| Biological |
cvp |
2 |
2005 |
| Drug |
cyclophosphamide 50mg |
2 |
2017 |
| Combination Product |
da-epoch-r |
2 |
2014 |
| Drug |
dabrafenib mesylate |
2 |
2020 |
| Biological |
daclizumab |
2 |
2000 |
| Drug |
decadron |
2 |
2007 |
| Drug |
defactinib hydrochloride |
2 |
2020 |
| Drug |
dexamethasone/prednisolone |
2 |
2005 |
| Other |
diagnostic laboratory biomarker analysis |
2 |
2010 |
| Drug |
dinaciclib |
2 |
2012 |
| Drug |
diphenhydramine |
2 |
2007 |
| Biological |
donor lymphocyte infusion (dli) |
2 |
2015 |
| Drug |
doxorubicine |
2 |
2009 |
| Biological |
dt2219arl |
2 |
2009 |
| Drug |
dtic |
2 |
2009 |
| Drug |
dtrm-555 |
2 |
2020 |
| Drug |
duration of treatment 6 months |
2 |
2004 |
| Drug |
ensartinib |
2 |
2017 |
| Drug |
entospletinib |
2 |
2017 |
| Drug |
epoch-f |
2 |
2015 |
| Drug |
epoch-r |
2 |
2000 |
| Biological |
erlotinib |
2 |
2008 |
| Drug |
erwinase |
2 |
2008 |
| Drug |
estramustine phosphate sodium |
2 |
2001 |
| Biological |
etanercept |
2 |
2005 |
| Behavioral |
exercise |
2 |
2014 |
| Other |
exercise training |
2 |
2019 |
| Radiation |
external beam radiation therapy |
2 |
2017 |
| Drug |
ezn-2208 |
2 |
2007 |
| Procedure |
fatigue assessment |
2 |
2008 |
| Procedure |
fatigue assessment/management |
2 |
2008 |
| Drug |
fgfr inhibitor azd4547 |
2 |
2020 |
| Biological |
filgrastim-sndz |
2 |
2019 |
| Biological |
filgrastim (g-csf) |
2 |
1999 |
| Drug |
flag |
2 |
2015 |
| Drug |
fludarabine phosphate (fludara) |
2 |
2008 |
| Drug |
fludarabine/busulfan |
2 |
2011 |
| Drug |
forodesine hydrochloride |
2 |
2004 |
| Drug |
fostamatinib |
2 |
2011 |
| Drug |
fulvestrant |
2 |
2015 |
| Drug |
ga101 |
2 |
2012 |
| Biological |
galiximab |
2 |
2007 |
| Biological |
gb226 |
2 |
2018 |
| Drug |
gdc-0980 |
2 |
2009 |
| Drug |
gemcitabine 1000 mg |
2 |
2018 |
| Drug |
gemcitabine, vinorelbine |
2 |
2005 |
| Genetic |
gene rearrangement analysis |
2 |
2008 |
| Biological |
genetically engineered lymphocyte therapy |
2 |
2011 |
| Drug |
glutamine |
2 |
2013 |
| Biological |
gp2013 |
2 |
2013 |
| Biological |
graft versus host disease prophylaxis |
2 |
2005 |
| Biological |
graft versus host disease prophylaxis/therapy |
2 |
2005 |
| Drug |
granulocyte colony-stimulating factor (g-csf) |
2 |
2018 |
| Biological |
haploidentical stem cell transplantation |
2 |
2015 |
| Drug |
hcd122 |
2 |
2011 |
| Biological |
hematopoietic stem cell transplant |
2 |
2009 |
| Drug |
hlx01 |
2 |
2017 |
| Drug |
hmpl-689 |
2 |
2018 |
| Drug |
hu5f9-g4 |
2 |
2018 |
| Drug |
hydrocortisone sodium succinate |
2 |
2014 |
| Drug |
ice |
2 |
2011 |
| Drug |
id-klh vaccine |
2 |
1999 |
| Drug |
idec-114 |
2 |
2007 |
| Biological |
ifn |
2 |
2006 |
| Drug |
imatinib |
2 |
2016 |
| Drug |
immunochemotherapy |
2 |
2011 |
| Drug |
imtox-25 |
2 |
2011 |
| Radiation |
indium in-111 ibritumomab tiuxetan |
2 |
2011 |
| Drug |
interferon |
2 |
2007 |
| Other |
internet-based intervention |
2 |
2008 |
| Drug |
intrathecal chemotherapy |
2 |
2016 |
| Drug |
intrathecal methotrexate |
2 |
2009 |
| Radiation |
involved-field radiotherapy |
2 |
2016 |
| Biological |
iodine-131 anti-b1 antibody |
2 |
2009 |
| Biological |
iodine i 131 tositumomab) |
2 |
2012 |
| Biological |
iph4102 |
2 |
2019 |
| Drug |
isavuconazole |
2 |
2014 |
| Drug |
isotretinoin |
2 |
2004 |
| Drug |
itacitinib |
2 |
2016 |
| Drug |
itraconazole |
2 |
2014 |
| Biological |
jwcar029 |
2 |
2017 |
| Biological |
keyhole limpet hemocyanin |
2 |
2000 |
| Biological |
kte-x19 |
2 |
2015 |
| Drug |
larotrectinib sulfate |
2 |
2017 |
| Drug |
lenalidomide/r-chop |
2 |
2009 |
| Biological |
lentivirus vector rhiv7-shi-tar-ccr5rz-transduced hematopoietic progenitor cells |
2 |
2013 |
| Drug |
liposomal cytarabine |
2 |
2003 |
| Biological |
lisocabtagene maraleucel |
2 |
2018 |
| Biological |
lmb-2 immunotoxin |
2 |
2004 |
| Biological |
lmp1 |
2 |
2003 |
| Drug |
lorlatinib |
2 |
2018 |
| Drug |
m^2 |
2 |
2008 |
| Biological |
mabthera |
2 |
2014 |
| Procedure |
management |
2 |
2008 |
| Drug |
mechlorethamine hydrochloride |
2 |
2007 |
| Drug |
medi4736 |
2 |
2015 |
| Drug |
meloxicam |
2 |
2013 |
| Drug |
melphalan hydrochloride |
2 |
2017 |
| Biological |
mem-enriched t-lymphocytes |
2 |
2014 |
| Drug |
metformin |
2 |
2018 |
| Drug |
metronidazole hydrochloride |
2 |
1999 |
| Drug |
mgcd0103 |
2 |
2006 |
| Drug |
midazolam |
2 |
2009 |
| Drug |
mk0683, vorinostat, suberoylanilide hydroxamic acid (saha) |
2 |
2004 |
| Drug |
mk0683, vorinostat, suberoylanilide hydroxamic acid (saha) / duration of treatment 6 months |
2 |
2004 |
| Drug |
mocetinostat |
2 |
2014 |
| Biological |
mor00208 |
2 |
2013 |
| Drug |
mt-3724 |
2 |
2018 |
| Drug |
mtx |
2 |
2014 |
| Other |
music therapy |
2 |
2011 |
| Biological |
natural killer cell therapy |
2 |
2012 |
| Other |
no treatment |
2 |
2005 |
| Drug |
obatoclax mesylate |
2 |
2007 |
| Drug |
ofatumumab / dhap |
2 |
2009 |
| Drug |
omeprazole, amoxicillin, clarithromycin |
2 |
2006 |
| Drug |
palonosetron |
2 |
2009 |
| Biological |
pbsc |
2 |
2000 |
| Other |
pbsct |
2 |
2007 |
| Drug |
pci-24781 |
2 |
2010 |
| Procedure |
peripheral blood draws |
2 |
2017 |
| Biological |
peripheral blood lymphocyte therapy |
2 |
1999 |
| Other |
peripheral blood stem cell infusion |
2 |
2007 |
| Procedure |
peripheral blood stem cell transplant |
2 |
2015 |
| Biological |
peripheral blood stem cells |
2 |
2016 |
| Drug |
pevonedistat |
2 |
2018 |
| Other |
pharmacodynamic studies |
2 |
2010 |
| placebo |
placebo to match ibrutinib |
2 |
2016 |
| Drug |
pn-196,444 |
2 |
2002 |
| Biological |
pneumococcal polyvalent vaccine |
2 |
2010 |
| Drug |
poly iclc |
2 |
2018 |
| Drug |
pqr309 |
2 |
2016 |
| Drug |
prednisone/prednisolone |
2 |
2010 |
| Drug |
ps-341 |
2 |
2005 |
| Other |
quality of life assessment |
2 |
2012 |
| Biological |
r |
2 |
2009 |
| Drug |
r-chop protocol |
2 |
2019 |
| Drug |
r-chop regimen |
2 |
2011 |
| Drug |
r-da-epoch-21 |
2 |
2018 |
| Drug |
r-da-epoch-21 / auto-sct |
2 |
2018 |
| Drug |
r-ice |
2 |
2018 |
| Drug |
r-idaram |
2 |
2016 |
| Drug |
r-idaram/intrathecal chemotherapy |
2 |
2016 |
| Biological |
rabbit atg |
2 |
2016 |
| Radiation |
radiation |
2 |
2015 |
| Drug |
radioimmunotherapy |
2 |
2006 |
| Drug |
rasburicase (sr29142) |
2 |
2008 |
| Drug |
recombinant human interleukin-2 |
2 |
2002 |
| Drug |
recombinant human interleukin-2/rituximab |
2 |
2002 |
| Biological |
recombinant human stem cell factor |
2 |
1999 |
| Biological |
recombinant interferon gamma |
2 |
1999 |
| Drug |
regn1979 |
2 |
2019 |
| Drug |
rituximab-chop |
2 |
2011 |
| Drug |
rituximab (r) |
2 |
2018 |
| Drug |
rituximab iv |
2 |
2014 |
| Drug |
rituximab sc |
2 |
2014 |
| Drug |
rp6530 |
2 |
2015 |
| Drug |
rrx-001 |
2 |
2015 |
| Drug |
ruxolitinib phosphate |
2 |
2017 |
| Drug |
samotolisib |
2 |
2017 |
| Drug |
sar245409 |
2 |
2011 |
| Drug |
sb1518 |
2 |
2010 |
| Drug |
sgn-35 |
2 |
2011 |
| Drug |
sgn-cd19a |
2 |
2013 |
| Drug |
silicon phthalocyanine 4 |
2 |
2013 |
| Biological |
silk |
2 |
2018 |
| Procedure |
single photon emission computed tomography |
2 |
2017 |
| Drug |
sodium phenylbutyrate |
2 |
2000 |
| Drug |
subcutaneous rituximab |
2 |
2014 |
| Drug |
sym022 |
2 |
2018 |
| Drug |
sym023 |
2 |
2017 |
| Device |
t cell |
2 |
2019 |
| Drug |
tafasitamab |
2 |
2016 |
| Drug |
taselisib |
2 |
2020 |
| Drug |
tetracycline hydrochloride |
2 |
1999 |
| Drug |
tg-0054 |
2 |
2011 |
| Drug |
tgr-1202 / ublituximab |
2 |
2017 |
| Procedure |
therapeutic conventional surgery |
2 |
2008 |
| Biological |
therapy |
2 |
2005 |
| Drug |
tislelizumab |
2 |
2020 |
| Drug |
tlr9 agonist sd-101 |
2 |
2018 |
| Drug |
tms |
2 |
2015 |
| Drug |
topotecan |
2 |
2007 |
| Radiation |
total lymphoid irradiation |
2 |
2007 |
| Procedure |
transplant |
2 |
2018 |
| Biological |
trastuzumab |
2 |
2016 |
| Biological |
trastuzumab emtansine |
2 |
2020 |
| Drug |
trimethoprim-sulfamethoxazole |
2 |
1999 |
| Drug |
triptorelin |
2 |
2012 |
| Biological |
trivalent baculovirus-expressed influenza ha vaccine |
2 |
2006 |
| Biological |
tumor cell-based vaccine therapy |
2 |
2000 |
| Biological |
umbilical cord blood |
2 |
2013 |
| Drug |
varlilumab |
2 |
2017 |
| Drug |
vincristine sulfate liposome |
2 |
2017 |
| Drug |
vincristine sulfate liposome injection |
2 |
2014 |
| Drug |
vinorelbine ditartrate |
2 |
1999 |
| Drug |
with r-chop |
2 |
2017 |
| Radiation |
yttrium y 90 anti-cd45 monoclonal antibody bc8 |
2 |
2013 |
| Radiation |
yttrium y 90 epratuzumab |
2 |
1999 |
| Drug |
-1 |
1 |
2016 |
| Drug |
-4 |
1 |
2016 |
| Drug |
-5 |
1 |
2016 |
| Procedure |
"interim gallium |
1 |
2006 |
| Procedure |
“interim gallium/pet/ct” |
1 |
2006 |
| Drug |
(pn-152,243)/ pn-196,444 |
1 |
2002 |
| Drug |
(pn-152,243)/pn-196,444 |
1 |
2002 |
| Drug |
(r-)chop protocol |
1 |
2007 |
| Drug |
[^14c]-alisertib |
1 |
2012 |
| Drug |
[14c] tazemetostat |
1 |
2016 |
| Radiation |
[18f]-fdg pet |
1 |
2018 |
| Radiation |
[18f]-fdg pet/mr |
1 |
2018 |
| Drug |
0.5 mg |
1 |
2013 |
| Drug |
0.5 mg/m2 di-leu16-il2 |
1 |
2013 |
| Drug |
01 |
1 |
2002 |
| Drug |
1 eshap courses. four more chemotherapy courses are delivered alternating eshap |
1 |
2018 |
| Drug |
1 eshap courses. six more chemotherapy courses are delivered alternating eshap |
1 |
2018 |
| Drug |
1.0 mg |
1 |
2013 |
| Drug |
1.0 mg/m2 di-leu16-il2 |
1 |
2013 |
| Biological |
10 mg |
1 |
2012 |
| Drug |
10 mg lenvatinib capsules). |
1 |
2012 |
| Biological |
10 mg/kg tru-016 / rituximab |
1 |
2012 |
| Drug |
10.0 mg |
1 |
2013 |
| Drug |
10.0 mg/m2 di-leu16-il2 |
1 |
2013 |
| Biological |
1000mg bat4306f |
1 |
2019 |
| Drug |
1018 iss |
1 |
2005 |
| Radiation |
111in-daclizumab |
1 |
2011 |
| Drug |
111in ibritumomab |
1 |
2011 |
| Biological |
12-day production of car-t cells |
1 |
2019 |
| Drug |
12 week stanford v chemotherapy |
1 |
2005 |
| Biological |
13 |
1 |
2020 |
| Radiation |
131iodine-anti-b1 radioimmunotherapy |
1 |
2007 |
| Drug |
17-n-allylamino-17-demethoxygeldanamycin |
1 |
2004 |
| Drug |
17-n-allylamino-17-demethoxygeldanamycin/bortezomib |
1 |
2004 |
| Drug |
18f-al-nota-prgd2 pet |
1 |
2015 |
| Drug |
18f-al-nota-prgd2 pet/ct |
1 |
2015 |
| Diagnostic Test |
18f-fdg |
1 |
2017 |
| Other |
18f-fdg pet scan |
1 |
2017 |
| Diagnostic Test |
18f-fluciclovine |
1 |
2017 |
| Biological |
19-28z t cells |
1 |
2013 |
| Drug |
2’-f-ara-deoxyuridine |
1 |
2008 |
| Drug |
2-cda |
1 |
2008 |
| Drug |
2 alternating cycles of vamp |
1 |
2005 |
| Drug |
2 alternating cycles of vamp/cop chemotherapy |
1 |
2005 |
| Biological |
2 ctls (alci - expansion - group a) |
1 |
2003 |
| Biological |
2 ctls (alci - expansion group b) |
1 |
2003 |
| Biological |
2 ctls (alci - expansion group c) |
1 |
2003 |
| Biological |
2 ctls (alci - group a) |
1 |
2003 |
| Biological |
2 ctls (alci - group b) |
1 |
2003 |
| Biological |
2 ctls (alci - group c) |
1 |
2003 |
| Drug |
2 ctls (group a) |
1 |
2013 |
| Drug |
2 ctls (group b) |
1 |
2013 |
| Drug |
2.0 mg |
1 |
2013 |
| Drug |
2.0 mg/m2 di-leu16-il2 |
1 |
2013 |
| Biological |
20-car vector-transduced t cells |
1 |
2017 |
| Radiation |
20 gy ifrt (involved field radiotherapy) |
1 |
2008 |
| Biological |
20 mg |
1 |
2012 |
| Biological |
20 mg/kg tru-016 / rituximab |
1 |
2012 |
| Biological |
22 |
1 |
2020 |
| Biological |
22-car vector-transduced t cells |
1 |
2017 |
| Genetic |
28zeta car t cells |
1 |
2017 |
| Drug |
2cda |
1 |
2008 |
| Device |
3’-deoxy-3’-[18f]fluorothymidine |
1 |
2009 |
| Drug |
3 alternating cycles of vamp |
1 |
2005 |
| Drug |
3 alternating cycles of vamp/cop chemotherapy |
1 |
2005 |
| Drug |
3) |
1 |
2014 |
| Drug |
3, |
1 |
2016 |
| Radiation |
30 grays |
1 |
2014 |
| Radiation |
30gy if-rt (involved-field radiotherapy) |
1 |
2011 |
| Radiation |
30gy in-rt (involved-node radiotherapy) |
1 |
2011 |
| Radiation |
3d-conformal radiotherapy (3d-crt) |
1 |
2012 |
| Behavioral |
3rp-lymphoma |
1 |
2017 |
| Drug |
4 |
1 |
2016 |
| Drug |
4 cycles of vamp chemotherapy |
1 |
2005 |
| Drug |
4.0 mg |
1 |
2013 |
| Drug |
4.0 mg/m2 di-leu16-il2 |
1 |
2013 |
| Procedure |
4fr) |
1 |
2006 |
| Drug |
4sc-205 |
1 |
2010 |
| Biological |
4scar19 |
1 |
2020 |
| Biological |
4scar19/4scar20/22/70/psma/13/79b/gd2 |
1 |
2020 |
| Biological |
4scar20 |
1 |
2020 |
| Drug |
5-azacitidine |
1 |
2017 |
| Drug |
5-flurouracil |
1 |
2008 |
| Drug |
5-fu |
1 |
2016 |
| Drug |
5-fu / cisplatin |
1 |
2016 |
| Biological |
500mg bat4306f |
1 |
2019 |
| Drug |
50mg |
1 |
2013 |
| Drug |
50mg/m2 rituximab |
1 |
2013 |
| Drug |
6-mercaptopurine,methotrexate |
1 |
2016 |
| Drug |
6-mercaptopurine. |
1 |
2018 |
| Drug |
6,8-bis(benzylthio)octanoic acid |
1 |
2014 |
| Drug |
6.0 mg |
1 |
2013 |
| Drug |
6.0 mg/m2 di-leu16-il2 |
1 |
2013 |
| Other |
68ga-dotanoc pet |
1 |
2014 |
| Other |
68ga-dotanoc pet/ct; diffusion weighted mri |
1 |
2014 |
| Drug |
68ga-pentixafor |
1 |
2017 |
| Biological |
70 |
1 |
2020 |
| Biological |
750mg bat4306f |
1 |
2019 |
| Biological |
79b |
1 |
2020 |
| Biological |
8-day production of car-t cells |
1 |
2019 |
| Drug |
8 cycles beacoppesc |
1 |
2009 |
| Drug |
8 cycles beacoppesc/goserelin |
1 |
2009 |
| Drug |
8 cycles beacoppesc/oral contraceptive |
1 |
2009 |
| Drug |
8.0 mg |
1 |
2013 |
| Drug |
8.0 mg/m2 di-leu16-il2 |
1 |
2013 |
| Other |
89zr-atezolizumab pet scans |
1 |
2019 |
| Drug |
9-ing-41 |
1 |
2018 |
| Biological |
90-y-ibritumomab tiuxetan |
1 |
2000 |
| Other |
90-y ibritumomab tiuxetan |
1 |
2005 |
| Biological |
900mg bat4306f |
1 |
2019 |
| Radiation |
90y-daclizumab |
1 |
2011 |
| Biological |
90y-hll2 |
1 |
2007 |
| Drug |
90y-ibritumomab |
1 |
2008 |
| Drug |
90y-ibritumomab tiuxetan (zevalin) |
1 |
2007 |
| Drug |
90y ibritumomabtiuxetan |
1 |
2011 |
| Drug |
90y zevalin |
1 |
2005 |
| Biological |
a-dmdt390-bisfv(ucht1) |
1 |
2008 |
| Drug |
a combination of them |
1 |
2013 |
| Drug |
â¸â¹zr-df-iab22m2c infusion |
1 |
2017 |
| Biological |
ab-205 |
1 |
2019 |
| Drug |
abb-r-chop |
1 |
2017 |
| Drug |
abemaciclib |
1 |
2012 |
| Drug |
abp 798 |
1 |
2016 |
| Drug |
abt-263 |
1 |
2006 |
| Drug |
abt-510 - thrombospondin-1 mimetic |
1 |
2003 |
| Drug |
abvd (adriamycin, bleomycin, vinblastine, dacarbazine) |
1 |
2011 |
| Drug |
abvd (adriamycin, bleomycin, vincristine, dacarbazine) |
1 |
2008 |
| Drug |
abvd chemotherapy regimen |
1 |
2015 |
| Drug |
abvd q4 weeks |
1 |
2007 |
| Drug |
abvd. |
1 |
2018 |
| Drug |
abvd/radiotherapy |
1 |
2008 |
| Drug |
abve-pc |
1 |
2013 |
| Drug |
ac0010ma |
1 |
2017 |
| Drug |
acalabrutinib in combination with bendamustine |
1 |
2016 |
| Drug |
acalabrutinib in combination with bendamustine/rituximab |
1 |
2016 |
| Drug |
acalabrutinib in combination with br |
1 |
2016 |
| Drug |
acalabrutinib in combination with vr |
1 |
2016 |
| Biological |
acellular pertussis vaccine adsorbed |
1 |
2015 |
| Drug |
acp-196 (acalabrutinib) |
1 |
2014 |
| Drug |
actonel (risedronate) |
1 |
2007 |
| Biological |
actr087 |
1 |
2016 |
| Biological |
actr707 |
1 |
2017 |
| Other |
acupuncture |
1 |
2009 |
| Drug |
acvbp regimen |
1 |
2005 |
| Drug |
acy-1215 |
1 |
2014 |
| Drug |
acyclovir |
1 |
2014 |
| Procedure |
adback nk |
1 |
2007 |
| Procedure |
adback nk/t cell |
1 |
2007 |
| Drug |
adct-301 |
1 |
2015 |
| Drug |
adct-402 |
1 |
2016 |
| Drug |
additional doses of rituximab |
1 |
2017 |
| Genetic |
adenovirus interferon gamma |
1 |
2006 |
| Drug |
adi-peg 20 |
1 |
2013 |
| Device |
administration of hyperbaric oxygen |
1 |
2014 |
| Drug |
adramycin |
1 |
2006 |
| Drug |
adriacin |
1 |
2016 |
| Drug |
adriamycin, vinblastine, |
1 |
2012 |
| Drug |
adriamycin, vinblastine,/dacarbazine |
1 |
2012 |
| Drug |
adriamycinâ® |
1 |
2006 |
| Drug |
adriblastin |
1 |
2006 |
| Drug |
adu-s100 |
1 |
2016 |
| Biological |
adult differentiated autologous t-cells |
1 |
2017 |
| Drug |
aeb071 |
1 |
2013 |
| Drug |
afatinib |
1 |
2015 |
| Drug |
aflibercept |
1 |
2008 |
| Drug |
afm 13 |
1 |
2010 |
| Drug |
ag-221 |
1 |
2014 |
| Drug |
ag-270 |
1 |
2018 |
| Drug |
ag-636 |
1 |
2019 |
| Biological |
ak105 |
1 |
2018 |
| Drug |
akt |
1 |
2015 |
| Drug |
akt/erk inhibitor onc201 |
1 |
2015 |
| Drug |
alefacept |
1 |
2007 |
| Drug |
alemtuzumab (campath-1h) |
1 |
2007 |
| Biological |
alemtuzumab (campath) |
1 |
2003 |
| Drug |
alemtuzumab (mabcampath) |
1 |
2005 |
| Drug |
alisertib (mln8237) |
1 |
2011 |
| Drug |
alkeran |
1 |
2006 |
| Genetic |
allo-501 |
1 |
2019 |
| Genetic |
allo-501a |
1 |
2020 |
| Procedure |
allo hct |
1 |
2019 |
| Procedure |
allogeneic cell transplantation |
1 |
2003 |
| Biological |
allogeneic cytomegalovirus-specific cytotoxic t lymphocytes |
1 |
2011 |
| Biological |
allogeneic dendritic cell electrofusion hybrid vaccine |
1 |
2009 |
| Procedure |
allogeneic hematopoietic cell transplantation |
1 |
2006 |
| Procedure |
allogeneic hematopoietic stem cell transplantation (hsct) |
1 |
2013 |
| Biological |
allogeneic natural killer cell line nk-92 |
1 |
2016 |
| Biological |
allogeneic nk cells |
1 |
2010 |
| Procedure |
allogeneic pbsct |
1 |
2008 |
| Procedure |
allogeneic pbsct/bmt |
1 |
2008 |
| Procedure |
allogeneic stem cell infusion |
1 |
2007 |
| Procedure |
allogeneic transplant |
1 |
2007 |
| Procedure |
allogeneic transplantation |
1 |
2011 |
| Drug |
allogenic stem cell transplant (asct) |
1 |
2007 |
| Biological |
allostim |
1 |
2007 |
| Drug |
alpha interferon |
1 |
2017 |
| Drug |
alrn-6924 |
1 |
2014 |
| Biological |
alt-803 |
1 |
2015 |
| Biological |
alt803 |
1 |
2016 |
| Biological |
altcar.cd30 cells |
1 |
2018 |
| Drug |
alternative anti-cancer treatment |
1 |
2012 |
| Drug |
alternative anticancer treatment |
1 |
2012 |
| Procedure |
alternative medicine procedure |
1 |
2003 |
| Drug |
alx148 |
1 |
2016 |
| Other |
ama (assistance for ambulatory patients) |
1 |
2017 |
| Drug |
amd3100 |
1 |
2008 |
| Biological |
ame-133v (ly2469298) |
1 |
2006 |
| Drug |
american ginseng |
1 |
2008 |
| Drug |
amg 319 |
1 |
2011 |
| Drug |
amg 562 |
1 |
2018 |
| Drug |
amg 655 |
1 |
2008 |
| Biological |
amg 714 |
1 |
2015 |
| Drug |
aminolevulinic acid hydrochloride |
1 |
2003 |
| Drug |
amp |
1 |
2010 |
| Drug |
amphotericin b deoxycholate |
1 |
1999 |
| Drug |
analgesic |
1 |
2008 |
| Drug |
analgesic/antipyretic/antihistamine drugs |
1 |
2008 |
| Drug |
aneustat (omn54) |
1 |
2012 |
| Drug |
anlotinib |
1 |
2018 |
| Procedure |
anthropometric measurement |
1 |
2012 |
| Biological |
anti-b1 antibody |
1 |
2009 |
| Biological |
anti-b1 antibody/iodine-131 anti-b1 antibody (tositumomab/iodine i 131 tositumomab) |
1 |
2009 |
| Biological |
anti-cd19- car |
1 |
2012 |
| Biological |
anti-cd19-car t cells |
1 |
2016 |
| Biological |
anti-cd19 car-t |
1 |
2019 |
| Biological |
anti-cd19 car-t cells injection |
1 |
2019 |
| Biological |
anti-cd19/20-car vector-transduced t cells |
1 |
2017 |
| Biological |
anti-cd19/22-car vector-transduced t cells |
1 |
2017 |
| Biological |
anti-cd20 b9e9 scfv-streptavidin fusion protein |
1 |
2015 |
| Biological |
anti-cd30-car t cells |
1 |
2017 |
| Genetic |
anti-cd30 car t cells |
1 |
2019 |
| Biological |
anti-cdl9-chimeric- antigen-receptor- transduced t cells |
1 |
2010 |
| Biological |
anti-cluster of differentiation 19 (cd19)-car pbl |
1 |
2009 |
| Biological |
anti-endosialin |
1 |
2012 |
| Biological |
anti-endosialin/tem1 monoclonal antibody morab-004 |
1 |
2012 |
| Biological |
anti-icos monoclonal antibody medi-570 |
1 |
2015 |
| Biological |
anti-ox40 antibody bms 986178 |
1 |
2018 |
| Drug |
anti-pd-1 antibody |
1 |
2019 |
| Drug |
anti-pd-1 monoclonal antibody |
1 |
2019 |
| Drug |
anti-thymocyte globulin (atg) |
1 |
2018 |
| Drug |
anti-thymocyte globulin (rabbit) |
1 |
2007 |
| Drug |
anti-thymocyte globulin iv |
1 |
2008 |
| Drug |
antibodies |
1 |
2005 |
| Procedure |
antibody-drug conjugate therapy |
1 |
2005 |
| Biological |
antigen-escalation stage |
1 |
2011 |
| Drug |
antihistamine drugs |
1 |
2008 |
| Drug |
antiï¼human thymoglobulin |
1 |
2016 |
| Drug |
antineoplaston therapy (atengenal |
1 |
1999 |
| Drug |
antineoplaston therapy (atengenal / astugenal) |
1 |
1999 |
| Drug |
antipyretic |
1 |
2008 |
| Drug |
ap1903 |
1 |
2018 |
| Other |
apbsct |
1 |
2009 |
| Drug |
apg-115 |
1 |
2016 |
| Drug |
apg-2575 |
1 |
2019 |
| Drug |
apixaban |
1 |
2015 |
| Drug |
aplidinâ® |
1 |
2009 |
| Drug |
apo866 |
1 |
2007 |
| Drug |
ar-12: (2-amino-n-[4-[5-(2 phenanthrenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl] phenyl]-acetamide) |
1 |
2009 |
| Drug |
ar-42 |
1 |
2010 |
| Drug |
ara c |
1 |
2014 |
| Drug |
aracytine |
1 |
2016 |
| Drug |
arginine butyrate |
1 |
2000 |
| Drug |
aroplatin |
1 |
2006 |
| Drug |
arq 092 |
1 |
2011 |
| Drug |
arq 531 |
1 |
2017 |
| Other |
ascr. |
1 |
2011 |
| Drug |
asct conditioning |
1 |
2016 |
| Drug |
asp3026 |
1 |
2011 |
| Drug |
asp4132 |
1 |
2015 |
| Drug |
astugenal) |
1 |
1999 |
| Drug |
at7519m |
1 |
2012 |
| Biological |
atezolizumab (anti-pd-l1) |
1 |
2016 |
| Drug |
atezolizumab (mpdl3280a) [tecentriq] |
1 |
2015 |
| Drug |
atezolizumab [tecentriq] |
1 |
2016 |
| Drug |
atg-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle |
1 |
2019 |
| Combination Product |
atg-019 / niacin er |
1 |
2020 |
| Biological |
atg (rabbit) |
1 |
2019 |
| Biological |
atlcar.cd30 t cells |
1 |
2019 |
| Biological |
atlcar.cd30.ccr4 cells |
1 |
2018 |
| Drug |
atorvastatin |
1 |
2005 |
| Drug |
atorvastatin calcium |
1 |
2012 |
| Drug |
atra |
1 |
2006 |
| Drug |
atra/g-csf (filgrastim, neupogen (r)) combination |
1 |
2006 |
| Drug |
auranofin |
1 |
2011 |
| Drug |
aurixim |
1 |
2017 |
| Drug |
aurora kinase inhibitor at9283 |
1 |
2007 |
| Procedure |
auto stem cell transplant |
1 |
2011 |
| Biological |
auto3 |
1 |
2017 |
| Biological |
auto4 |
1 |
2018 |
| Other |
autologous (auto) peripheral blood stem cell transplantation |
1 |
2010 |
| Biological |
autologous ade1- latent membrane protein ctls |
1 |
2008 |
| Biological |
autologous anti-cd19 car t cells |
1 |
2016 |
| Biological |
autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing cd4 |
1 |
2016 |
| Biological |
autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing cd4//cd8/ central memory t-lymphocytes jcar014 |
1 |
2016 |
| Biological |
autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing t lymphocytes |
1 |
2013 |
| Procedure |
autologous blood stem transplantation |
1 |
2007 |
| Drug |
autologous car.cd30 ebv specific-ctls |
1 |
2010 |
| Drug |
autologous cd22 car t |
1 |
2019 |
| Drug |
autologous chimeric antigen receptor t cell transfusing agent targeting cd22 |
1 |
2019 |
| Biological |
autologous dendritic cell-tumor fusion vaccine |
1 |
2010 |
| Biological |
autologous dendritic cell electrofusion hybrid vaccine |
1 |
2009 |
| Biological |
autologous dendritic cells |
1 |
2016 |
| Biological |
autologous epstein-barr virus-specific cytotoxic t lymphocytes |
1 |
2000 |
| Biological |
autologous fl vaccine |
1 |
2009 |
| Procedure |
autologous hct |
1 |
2006 |
| Procedure |
autologous hematopoietic stem cell harvesting |
1 |
2006 |
| Procedure |
autologous hematopoietic stem cell harvesting/transplantation |
1 |
2006 |
| Biological |
autologous human anti-cd19car-4-1bb-cd3zeta-egfrt-expressing cd4 |
1 |
2017 |
| Biological |
autologous human anti-cd19car-4-1bb-cd3zeta-egfrt-expressing cd4//cd8/ t-lymphocytes |
1 |
2017 |
| Drug |
autologous human tumor-derived hsppc-96 |
1 |
2004 |
| Biological |
autologous î³î´t cells |
1 |
2019 |
| Biological |
autologous immunoglobulin idiotype-klh conjugate vaccine |
1 |
2003 |
| Biological |
autologous lymphoma cell |
1 |
2009 |
| Biological |
autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine |
1 |
2009 |
| Biological |
autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine |
1 |
2009 |
| Biological |
autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine |
1 |
2009 |
| Biological |
autologous lymphoma immunoglobulin-derived scfv-chemokine dna vaccine |
1 |
2010 |
| Procedure |
autologous stem-cell transplantation |
1 |
2007 |
| Procedure |
autologous stem cell transplant (asct) |
1 |
2011 |
| Drug |
autologous stem cell transplant in responders. |
1 |
2017 |
| Procedure |
autologous transplant |
1 |
2010 |
| Drug |
autologous transplantation using bexxar |
1 |
2006 |
| Drug |
autologous transplantation using bexxar/beam |
1 |
2006 |
| Drug |
autologous transplantation using rituxan |
1 |
2006 |
| Drug |
autologous transplantation using rituxan/beam |
1 |
2006 |
| Biological |
autologous tumor cell-based vaccine |
1 |
2005 |
| Biological |
autologous tumor cell vaccine |
1 |
2001 |
| Procedure |
autologous/allogeneic stem cell transplantation |
1 |
2018 |
| Biological |
autologous/syngeneic pbtls/ebv-ctls |
1 |
2008 |
| Procedure |
autotransplant |
1 |
2005 |
| Procedure |
autrotransplant |
1 |
2006 |
| Biological |
av-299 |
1 |
2008 |
| Biological |
av-299 / erlotinib |
1 |
2008 |
| Drug |
avadomide (cc-122) |
1 |
2017 |
| Drug |
avl-292 |
1 |
2011 |
| Drug |
avn-944 capsules for oral administration |
1 |
2006 |
| Drug |
azacitadine |
1 |
2014 |
| Drug |
azacitidine injection |
1 |
2000 |
| Drug |
azacitidine with rituximab, vincristine, |
1 |
2009 |
| Drug |
azacitidine with rituximab, vincristine,/cyclophosphamide |
1 |
2009 |
| Biological |
azacytidine/multitaa t cells stage |
1 |
2011 |
| Drug |
azd 2014 |
1 |
2016 |
| Drug |
azd1152 |
1 |
2011 |
| Drug |
azd1208 |
1 |
2012 |
| Drug |
azd3965 |
1 |
2013 |
| Drug |
azd4205 |
1 |
2019 |
| Drug |
azd4573 |
1 |
2017 |
| Drug |
azd5991 |
1 |
2017 |
| Drug |
azd5991 / venetoclax |
1 |
2017 |
| Drug |
azd6738 |
1 |
2018 |
| Drug |
b-all protocol |
1 |
2007 |
| Drug |
b-cap |
1 |
2014 |
| Drug |
b-mad chemotherapy |
1 |
2017 |
| Biological |
b001 |
1 |
2017 |
| Biological |
basiliximab |
1 |
2011 |
| Drug |
batracylin |
1 |
2007 |
| Drug |
bay1862864 |
1 |
2015 |
| Drug |
bay1895344 |
1 |
2017 |
| Drug |
bcd chemotherapy (bendamustine, carboplatin, dexamethasone) |
1 |
2015 |
| Drug |
bcl201 |
1 |
2015 |
| Biological |
bcma-cd19 ccar t cells |
1 |
2019 |
| Drug |
bcx-1777 |
1 |
2002 |
| Drug |
beacopp |
1 |
2010 |
| Drug |
beacopp escalated |
1 |
2007 |
| Drug |
beacopp escalated q3 weeks |
1 |
2007 |
| Drug |
beacopp regimen |
1 |
2009 |
| Drug |
beacoppesc |
1 |
2011 |
| Drug |
beacoppesc - abvd - pet2 |
1 |
2011 |
| Drug |
beacoppescalated (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) |
1 |
2011 |
| Drug |
beam (carmustine (bcnu), etoposide, cytarabine, melphalan) |
1 |
2007 |
| Procedure |
beam chemotherapy |
1 |
2007 |
| Procedure |
beam chemotherapy/autologous stem-cell transplantation |
1 |
2007 |
| Drug |
beeam |
1 |
2014 |
| Drug |
beeam regimen |
1 |
2017 |
| Drug |
bendamustine-eam |
1 |
2011 |
| Drug |
bendamustine (ben) |
1 |
2016 |
| Drug |
bendamustine / rituximab / pixantrone |
1 |
2011 |
| Drug |
bendamustine 90 mg |
1 |
2016 |
| Drug |
bendamustine 90 mg/m2 iv on days 1-2, cycles 1-6 |
1 |
2016 |
| Drug |
bendamustine at a dose of 100 mg |
1 |
2011 |
| Drug |
bendamustine at a dose of 100 mg/m2 |
1 |
2011 |
| Drug |
bendamustine at a dose of 120 mg |
1 |
2011 |
| Drug |
bendamustine at a dose of 120 mg/m2 |
1 |
2011 |
| Drug |
bendamustine, lenalidomide, rituximab |
1 |
2012 |
| Drug |
bendamustine, rituximab |
1 |
2016 |
| Drug |
bendamustine/lenalidomide |
1 |
2009 |
| Drug |
bendamustine/subcutaneous rituximab |
1 |
2012 |
| Other |
best available therapy |
1 |
2017 |
| Drug |
bexarotene capsules |
1 |
2010 |
| Drug |
bgb-10188 |
1 |
2020 |
| Biological |
bi-1206 single agent dose escalation phase |
1 |
2016 |
| Biological |
bi-1206 single agent expansion phase |
1 |
2016 |
| Drug |
bi-weekly chop |
1 |
2005 |
| Drug |
bi 2536 |
1 |
2005 |
| Drug |
bi 695500 |
1 |
2013 |
| Biological |
bi1206 |
1 |
2018 |
| Drug |
bimiralisib |
1 |
2014 |
| Biological |
biological therapy |
1 |
2017 |
| Procedure |
biospecimen collection |
1 |
2017 |
| Drug |
birinapant (tl32711) |
1 |
2009 |
| Dietary Supplement |
bismuth subcitrate |
1 |
1999 |
| Drug |
bismuth subsalicylate |
1 |
1999 |
| Drug |
bismuth tablets |
1 |
2009 |
| Drug |
biweekly-chop with g-csf |
1 |
2005 |
| Drug |
biweekly-chop with g-csf/intrathecal prophylaxis |
1 |
2005 |
| Drug |
bl-nhl |
1 |
2009 |
| Drug |
bl22 immunotoxin |
1 |
2005 |
| Biological |
bleomycin sulfate (blm) |
1 |
1999 |
| Biological |
blinatumomab (mt103) |
1 |
2006 |
| Biological |
blinatumomab expanded t-cells (bet) |
1 |
2019 |
| Procedure |
blood draw |
1 |
2007 |
| Procedure |
blood/marrow transplant (bmt) |
1 |
2019 |
| Drug |
blr-cll |
1 |
2009 |
| Drug |
blr-nhl |
1 |
2009 |
| Drug |
bms-247550 |
1 |
2002 |
| Drug |
bms-906024 |
1 |
2011 |
| Procedure |
bmt |
1 |
2008 |
| Device |
bodyfix |
1 |
2005 |
| Procedure |
bone marrow collection |
1 |
2018 |
| Procedure |
bone marrow histology |
1 |
2019 |
| Other |
bone marrow transplant (bmt) |
1 |
2019 |
| Procedure |
bone marrow transplantation |
1 |
1999 |
| Radiation |
boost 6 gy residual) |
1 |
2007 |
| Drug |
bortezomib (b) |
1 |
2005 |
| Drug |
bortezomib (drug) |
1 |
2005 |
| Drug |
bortezomib, chop, rituximab |
1 |
2005 |
| Drug |
bortezomib, cytarabine, dexamethasone, pegteograstim |
1 |
2016 |
| Drug |
bortezomib, dexamethasone, ifosfamide |
1 |
2007 |
| Drug |
bortezomib, rituximab, ifosphamide, etoposide, carboplatin |
1 |
2010 |
| Drug |
bortezomib, tositumomab |
1 |
2008 |
| Drug |
bortezomib/clofarabine |
1 |
2014 |
| Drug |
bortezomib/dexamethasone |
1 |
2018 |
| Drug |
bortezomib/g-csf |
1 |
2010 |
| Drug |
bortezomib/observation |
1 |
2005 |
| Drug |
bortezomib/tositumomab i-131 |
1 |
2007 |
| Drug |
br-dhap |
1 |
2013 |
| Drug |
br-i (bendamustine, rituximab, ibrutinib) |
1 |
2017 |
| Biological |
brentuximab |
1 |
2017 |
| Drug |
brentuximab vedotin - induction |
1 |
2018 |
| Drug |
brentuximab vedotin - maintenance |
1 |
2018 |
| Drug |
brentuximab vedotin (bv) |
1 |
2018 |
| Drug |
brentuximab vedotin/rifampicin |
1 |
2013 |
| Drug |
brentuximabvedotin (bv) |
1 |
2018 |
| Drug |
btct4465a (mosunetuzumab) iv |
1 |
2015 |
| Drug |
btct4465a (mosunetuzumab) sc |
1 |
2015 |
| Drug |
btk inhibitor pci-32765 |
1 |
2011 |
| Drug |
buparlisib (bkm120) |
1 |
2014 |
| Drug |
busulfan (conditioning for allo transplant) |
1 |
2010 |
| Drug |
busulfan (conditioning for auto transplant) |
1 |
2010 |
| Drug |
busulfan x 4 |
1 |
2007 |
| Drug |
busulfan, fludarabine, cytoxan |
1 |
2008 |
| Drug |
busulfan, melphalan |
1 |
2005 |
| Drug |
busulfan, melphalan, fludarabine, g-csf |
1 |
2007 |
| Drug |
busulfan/fludarabine |
1 |
2011 |
| Drug |
bvd) |
1 |
2011 |
| Biological |
c-car-011 |
1 |
2016 |
| Drug |
c-car066 |
1 |
2020 |
| Drug |
c-cpt |
1 |
2016 |
| Drug |
c46) drug product |
1 |
2018 |
| Drug |
ca-170 |
1 |
2016 |
| Drug |
cabiralizumab |
1 |
2019 |
| Drug |
cal-1 (lvsh5 |
1 |
2018 |
| Drug |
cal-1 (lvsh5/c46) drug product |
1 |
2018 |
| Drug |
calaspargase pegol |
1 |
2018 |
| Dietary Supplement |
calcium |
1 |
2007 |
| Drug |
calcium-dtpa |
1 |
1999 |
| Drug |
calcium carbonate |
1 |
2006 |
| Drug |
camidanlumab tesirine |
1 |
2019 |
| Drug |
campth-1h |
1 |
2005 |
| Drug |
camptothecin-20-o-propionate hydrate (cz48) |
1 |
2009 |
| Drug |
camrelizumab(shr-1210) |
1 |
2020 |
| Drug |
can be any registered nonpegylated form of g-csf |
1 |
2008 |
| Drug |
canfosfamide hcl for injection |
1 |
2010 |
| Drug |
capa indution immunotherapy |
1 |
2020 |
| Other |
caphosol |
1 |
2013 |
| Biological |
car-cd19 t cells |
1 |
2019 |
| Biological |
car-t cell therapy |
1 |
2019 |
| Biological |
car-t19 |
1 |
2019 |
| Biological |
car-t19/car-t22 |
1 |
2019 |
| Biological |
car-t22 |
1 |
2019 |
| Genetic |
car t cells |
1 |
2016 |
| Drug |
car.cd30 t cells |
1 |
2011 |
| Drug |
carboplatin. |
1 |
2018 |
| Drug |
carboplatine |
1 |
2005 |
| Drug |
carboxyamidotriazole |
1 |
2001 |
| Behavioral |
carevive careplanning system |
1 |
2019 |
| Drug |
carmustine bcnu |
1 |
2007 |
| Drug |
carmustine, etoposide, cytarabine, melphalan |
1 |
2015 |
| Drug |
cart |
1 |
2008 |
| Other |
cart-19 cells |
1 |
2017 |
| Biological |
cart30 |
1 |
2014 |
| Drug |
carvedilol |
1 |
2010 |
| Drug |
caspofungin acetate |
1 |
2001 |
| Drug |
cat-8015 (moxetumomab pasudotox) |
1 |
2008 |
| Drug |
cat-8015 20 mcg |
1 |
2009 |
| Drug |
cat-8015 20 mcg/kg |
1 |
2009 |
| Drug |
cat-8015 30 mcg |
1 |
2009 |
| Drug |
cat-8015 30 mcg/kg |
1 |
2009 |
| Drug |
cat-8015 40 mcg |
1 |
2009 |
| Drug |
cat-8015 40 mcg/kg |
1 |
2009 |
| Drug |
cat-8015 50 mcg |
1 |
2009 |
| Drug |
cat-8015 50 mcg/kg |
1 |
2009 |
| Drug |
cat-8015 60 mcg |
1 |
2009 |
| Drug |
cat-8015 60 mcg/kg |
1 |
2009 |
| Drug |
cc-220 |
1 |
2017 |
| Drug |
cc-292 / lenalidomide |
1 |
2012 |
| Drug |
cc-486 |
1 |
2014 |
| Drug |
cc-486 administration |
1 |
2018 |
| Drug |
cc-90010 |
1 |
2017 |
| Drug |
cc-90011 |
1 |
2016 |
| Drug |
cc-95775 |
1 |
2019 |
| Biological |
cc-97540 |
1 |
2020 |
| Drug |
cc-99282 |
1 |
2019 |
| Radiation |
ccrt |
1 |
2010 |
| Other |
ccrt followed by vidl chemotherapy |
1 |
2009 |
| Radiation |
ccrt/midle chemotherapy |
1 |
2010 |
| Drug |
cd11301 0.03% |
1 |
2017 |
| Drug |
cd11301 0.06% |
1 |
2017 |
| Biological |
cd133 |
1 |
2014 |
| Biological |
cd133/ selected autologous stem cell infusion |
1 |
2014 |
| Biological |
cd19-7ã—19 car-t |
1 |
2020 |
| Biological |
cd19-7ã—19 car-t/pd1 monoclonal antibody |
1 |
2020 |
| Drug |
cd19-cart |
1 |
2019 |
| Biological |
cd19-cd34 car transduced t cells |
1 |
2019 |
| Biological |
cd19-directed car-t cells |
1 |
2018 |
| Biological |
cd19-pd1-cart cell |
1 |
2019 |
| Biological |
cd19-specific chimeric antigen receptor t cells with pd1 knockout |
1 |
2019 |
| Procedure |
cd19-specific t cell infusion |
1 |
2009 |
| Biological |
cd19-targeted chimeric antigen receptor (car) t cells |
1 |
2019 |
| Biological |
cd19-targeting car t cells infusion |
1 |
2015 |
| Biological |
cd19 car-t cells infusion |
1 |
2020 |
| Combination Product |
cd19 cart |
1 |
2019 |
| Biological |
cd19 targeted chimeric antigen receptor t cells |
1 |
2017 |
| Biological |
cd19.car t cells |
1 |
2018 |
| Biological |
cd19/ |
1 |
2019 |
| Biological |
cd19/cd20 bispecific car-t cells |
1 |
2019 |
| Biological |
cd19/cd22 car t-cells |
1 |
2018 |
| Genetic |
cd19car-28-zeta t cells |
1 |
2007 |
| Biological |
cd19cat-41bbz car t-cells |
1 |
2016 |
| Biological |
cd20 |
1 |
2018 |
| Biological |
cd20-directed car-t cells |
1 |
2019 |
| Biological |
cd20 bispecific car-t cells |
1 |
2019 |
| Biological |
cd20 car-t |
1 |
2019 |
| Biological |
cd22-car |
1 |
2014 |
| Drug |
cd22 car-t cell immunotherapy |
1 |
2018 |
| Biological |
cd22 car-t cells |
1 |
2018 |
| Biological |
cd22 car t-cells |
1 |
2018 |
| Biological |
cd3-depleted |
1 |
2011 |
| Biological |
cd3-depleted/cd56/ selected natural killer cells collected from apheresis products |
1 |
2011 |
| Procedure |
cd34 |
1 |
2015 |
| Procedure |
cd34/ cell selection |
1 |
2015 |
| Other |
cd4 dli |
1 |
2010 |
| Biological |
cd45ra-depleted dli |
1 |
2019 |
| Device |
cd45ra depleted peripheral stem cell addback |
1 |
2019 |
| Biological |
cd4car |
1 |
2018 |
| Genetic |
cd5.car |
1 |
2017 |
| Genetic |
cd5.car/28zeta car t cells |
1 |
2017 |
| Biological |
cd56 |
1 |
2011 |
| Biological |
cd56-enriched donor lymphocyte infusion |
1 |
2018 |
| Drug |
cd5789 0.01% cream |
1 |
2013 |
| Biological |
cd7-specific car gene-engineered t cells |
1 |
2019 |
| Drug |
cd7 car-t cells infusion |
1 |
2019 |
| Drug |
cddo |
1 |
2006 |
| Drug |
cdki at7519 |
1 |
2006 |
| Drug |
cdope |
1 |
2015 |
| Drug |
cdx-1127 |
1 |
2011 |
| Drug |
cdx-1140 |
1 |
2017 |
| Drug |
cediranib maleate |
1 |
2007 |
| Drug |
ceep-rituximab |
1 |
2007 |
| Drug |
ceep regimen |
1 |
2009 |
| Drug |
cefepime hydrochloride |
1 |
2011 |
| Procedure |
cell selection |
1 |
2015 |
| Drug |
cellcept |
1 |
2018 |
| Drug |
cemiplimab |
1 |
2016 |
| Drug |
cemiplimab regn2810 |
1 |
2018 |
| Biological |
central memory t-lymphocytes jcar014 |
1 |
2016 |
| Drug |
central nervous system (cns) prophylaxis |
1 |
2007 |
| Drug |
ceop |
1 |
2015 |
| Drug |
ceop chemotherapy regimen for 6 cycles |
1 |
2015 |
| Drug |
ceop regimen |
1 |
2009 |
| Drug |
ceop/ive/gdp chemotherapy regimen |
1 |
2015 |
| Drug |
cep-18770 |
1 |
2007 |
| Drug |
cep-9722 |
1 |
2011 |
| Drug |
cerdulatinib (prt062070) |
1 |
2013 |
| Drug |
ceritinib |
1 |
2012 |
| Drug |
cg-806 |
1 |
2019 |
| Drug |
cgc-11047 |
1 |
2008 |
| Drug |
cgc-11047/5-flurouracil / leucovorin |
1 |
2008 |
| Drug |
cgc-11047/bevacizumab |
1 |
2008 |
| Drug |
cgc-11047/cisplatin |
1 |
2008 |
| Drug |
cgc-11047/docetaxel |
1 |
2008 |
| Drug |
cgc-11047/erlotinib |
1 |
2008 |
| Drug |
cgc-11047/gemcitabine |
1 |
2008 |
| Drug |
cgc-11047/sunitinib |
1 |
2008 |
| Biological |
chemokine (c-c motif) ligand 19-expressing cd19-car-t cells |
1 |
2019 |
| Drug |
chemotherapy-rituximab combination |
1 |
2011 |
| Drug |
chemotherapy (induction period) |
1 |
2011 |
| Other |
chemotherapy followed by radiotherapy |
1 |
2015 |
| Drug |
chemotherapy followed by zevalin |
1 |
2007 |
| Drug |
chemotherapy with |
1 |
2008 |
| Drug |
chemotherapy with/without radiotherapy |
1 |
2008 |
| Drug |
chemotherapy/radioimmunotherapy |
1 |
2005 |
| Drug |
chep |
1 |
2017 |
| Drug |
chidamide / r-chop regimen |
1 |
2017 |
| Drug |
chidamide, lenalidomide |
1 |
2020 |
| Drug |
chidamide, rituximab, gemcitabine,oxaliplatin |
1 |
2019 |
| Drug |
chidamide/with r-gdp |
1 |
2017 |
| Biological |
chimeric anti-cd20 monoclonal antibody |
1 |
2014 |
| Biological |
chimeric antigen receptor modified t cells targeting cd19 |
1 |
2015 |
| Drug |
chlorambucil (drug) |
1 |
2005 |
| Drug |
choep |
1 |
2008 |
| Drug |
choep / g-csf followed by beam |
1 |
2008 |
| Drug |
chop-daclizumab |
1 |
2011 |
| Drug |
chop-r |
1 |
2005 |
| Drug |
chop (cyclophosphamide (c), adriamycin (h), vincristine (o), |
1 |
2006 |
| Drug |
chop (cyclophosphamide (c), adriamycin (h), vincristine (o),/prednisone (p)) chemotherapy |
1 |
2006 |
| Drug |
chop (cyclophosphamide, hydroxydaunorubicin [doxorubicin], oncovin [vincristine], prednisone) |
1 |
2008 |
| Procedure |
chop / tbi/autotransplant |
1 |
2005 |
| Drug |
chop administration |
1 |
2018 |
| Drug |
chop chemotherapy |
1 |
2005 |
| Drug |
chop regimen alternate with eshap regimen |
1 |
2009 |
| Drug |
chop, cmab304 |
1 |
2011 |
| Drug |
chop/alemtuzumab |
1 |
2005 |
| Drug |
chop/famotidine |
1 |
2018 |
| Drug |
chop/lanzoprazole |
1 |
2018 |
| Drug |
chop/with cmab304 |
1 |
2011 |
| Drug |
chop14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) |
1 |
2008 |
| Drug |
chop14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison)/g-csf,/with alemtuzumab |
1 |
2008 |
| Drug |
chop14 chemotherapy (see specification under arm b) |
1 |
2008 |
| Drug |
chop14 chemotherapy (see specification under arm b)/g-csf |
1 |
2008 |
| Drug |
chop21 |
1 |
2009 |
| Drug |
chop21-r |
1 |
2009 |
| Drug |
chope |
1 |
2015 |
| Procedure |
chvp |
1 |
2005 |
| Procedure |
chvp / interferon |
1 |
2005 |
| Drug |
cinobufacini tablets |
1 |
2016 |
| Drug |
cirmtuzumab |
1 |
2017 |
| Drug |
cirmtuzumab/ibrutinib |
1 |
2017 |
| Drug |
cisplatin (cddp) |
1 |
1999 |
| Drug |
cisplatin, vipd |
1 |
2007 |
| Drug |
cisplatine |
1 |
2005 |
| Drug |
ck-301 (cosibelimab) |
1 |
2017 |
| Drug |
ckd-581 |
1 |
2012 |
| Drug |
clarithromycin/lenalidomide |
1 |
2017 |
| Drug |
clearing agent |
1 |
2015 |
| Procedure |
clin a. chop-campath (chemo-immunotherapy) |
1 |
2012 |
| Procedure |
clin a. chop-campath (chemo-immunotherapy) / sct |
1 |
2012 |
| Drug |
clin b (chop- campath) chemo-immunotherapy |
1 |
2012 |
| Other |
clinical observation |
1 |
2011 |
| Other |
clinical/laboratory evaluations |
1 |
2015 |
| Diagnostic Test |
clinical/laboratory parameters |
1 |
2019 |
| Device |
clinimacs cd34 |
1 |
2014 |
| Device |
clinimacs cd34/ reagent system |
1 |
2014 |
| Device |
clinimacs cell processing system for tcrî±î² |
1 |
2019 |
| Device |
clinimacs cell processing system for tcrî±î² / t cell/cd45ra depleted peripheral stem cell addback |
1 |
2019 |
| Drug |
clofarabine/busulfan x 4 |
1 |
2007 |
| Drug |
clr 131 |
1 |
2018 |
| Drug |
clr 131 fractionated dose |
1 |
2016 |
| Drug |
clr 131 multiple dose |
1 |
2016 |
| Drug |
clr 131 single dose |
1 |
2016 |
| Drug |
cmp-001 |
1 |
2019 |
| Biological |
cmvpp65-a*0201 peptide vaccine |
1 |
2015 |
| Procedure |
cns irradiation |
1 |
2005 |
| Drug |
cnto 328 |
1 |
2006 |
| Combination Product |
codox-m |
1 |
2018 |
| Combination Product |
codox-m/ivac |
1 |
2018 |
| Procedure |
cognitive assessment |
1 |
2015 |
| Behavioral |
cognitive behavior therapy |
1 |
2018 |
| Behavioral |
cognitive behavioral therapy for treating fatigue |
1 |
2018 |
| Other |
cohort |
1 |
2016 |
| Procedure |
collection |
1 |
2018 |
| Other |
collection of blood specimen |
1 |
2012 |
| Biological |
combination of bi-1206 with rituximab |
1 |
2016 |
| Other |
combination of treatment modalities |
1 |
2010 |
| Genetic |
comparative genomic hybridization |
1 |
2011 |
| Procedure |
complementary |
1 |
2003 |
| Procedure |
complementary/alternative medicine procedure |
1 |
2003 |
| Drug |
concurrent radiotherapy (rt) |
1 |
2007 |
| Drug |
concurrent radiotherapy (rt)/cisplatin, vipd |
1 |
2007 |
| Device |
confocal laser endomicroscope |
1 |
2012 |
| Procedure |
confocal laser endomicroscopy |
1 |
2012 |
| Procedure |
consolidation treatment part 1: hd-chemotherapy with asct |
1 |
2007 |
| Radiation |
consolidation treatment part 2: radiotherapy |
1 |
2007 |
| Radiation |
consolidation volume rt (cvrt) |
1 |
2013 |
| Procedure |
contrast-enhanced magnetic resonance imaging |
1 |
2007 |
| Other |
control |
1 |
2019 |
| Radiation |
conventional photon radiation plan |
1 |
2009 |
| Drug |
conventional vincristine |
1 |
2011 |
| Drug |
cop chemotherapy |
1 |
2005 |
| Drug |
cop, copadm8, cyve |
1 |
2010 |
| Drug |
cop, copd m3, cym |
1 |
2010 |
| Drug |
copad |
1 |
2010 |
| Biological |
cord blood |
1 |
2011 |
| Biological |
cord blood-derived expanded allogeneic natural killer cells |
1 |
2017 |
| Biological |
cord blood stem cells |
1 |
2019 |
| Other |
cord blood unit |
1 |
2016 |
| Procedure |
correlative |
1 |
2009 |
| Other |
correlative laboratory samples |
1 |
2012 |
| Procedure |
correlative/special studies |
1 |
2009 |
| Other |
counseling intervention |
1 |
2008 |
| Biological |
cpg-mcl vaccine |
1 |
2007 |
| Drug |
cpg 7909 |
1 |
2005 |
| Drug |
cpi-0610 |
1 |
2013 |
| Drug |
cpi-1205 |
1 |
2015 |
| Drug |
cpi-613 |
1 |
2019 |
| Drug |
cpi-818 |
1 |
2019 |
| Drug |
cpi 613 |
1 |
2019 |
| Drug |
cpop-r |
1 |
2005 |
| Drug |
cpx-351 |
1 |
2013 |
| Procedure |
cranial irradiation |
1 |
2016 |
| Radiation |
cranial radiotherapy |
1 |
2009 |
| Procedure |
cryosurgery |
1 |
2017 |
| Procedure |
cryotherapy |
1 |
2010 |
| Drug |
cs-1008 (humanized anti-dr5 antibody) |
1 |
2006 |
| Drug |
cs1003 monoclonal antibody |
1 |
2019 |
| Procedure |
csf analysis |
1 |
2010 |
| Other |
ct after 1 cycle of r-chop |
1 |
2011 |
| Radiation |
ct coronary angiography |
1 |
2011 |
| Other |
ct post 2 cycles of chemotherapy |
1 |
2006 |
| Procedure |
ct" |
1 |
2006 |
| Other |
ct; diffusion weighted mri |
1 |
2014 |
| Biological |
ctl019 |
1 |
2015 |
| Drug |
ctx |
1 |
2014 |
| Biological |
ctx110 |
1 |
2019 |
| Drug |
curcumin |
1 |
2014 |
| Drug |
cvp (cyclophosphamide, vincristine, prednisone) |
1 |
2008 |
| Drug |
cx-072 |
1 |
2016 |
| Drug |
cx-2029 |
1 |
2018 |
| Drug |
cx-3543 |
1 |
2009 |
| Drug |
cyclo, vcr, pred, dacarb,etop |
1 |
2015 |
| Drug |
cyclo, vcr, pred, dacarb,etop/doxo |
1 |
2015 |
| Drug |
cyclophosphamide (conditioning for auto transplant) |
1 |
2010 |
| Drug |
cyclophosphamide 14.5 mg |
1 |
2016 |
| Drug |
cyclophosphamide 14.5 mg/kg/day iv on days -6, -5 |
1 |
2016 |
| Drug |
cyclophosphamide 50mg/kg/day iv on days -2,-1 |
1 |
2016 |
| Drug |
cyclophosphamide 50mg/kg/day iv on days -5,-4 |
1 |
2016 |
| Drug |
cyclophosphamide 750 mg |
1 |
2008 |
| Drug |
cyclophosphamide 750 mg/m^2 |
1 |
2008 |
| Drug |
cyclophosphamide 750mg |
1 |
2017 |
| Drug |
cyclophosphamide 750mg/m2 by iv infusion |
1 |
2017 |
| Drug |
cyclophosphamide doxorubicin vincristine lamivudine |
1 |
2005 |
| Drug |
cyclophosphamide epirubicin etoposide prednisolone |
1 |
2005 |
| Drug |
cyclophosphamide) |
1 |
2014 |
| Drug |
cyclophosphamide, doxorubicin, vincristine |
1 |
2012 |
| Drug |
cyclophosphamide, doxorubicin, vincristine, |
1 |
2001 |
| Drug |
cyclophosphamide, doxorubicin, vincristine,/prednisone (chop) |
1 |
2001 |
| Drug |
cyclophosphamide, doxorubicin, vincristine/prednisone |
1 |
2012 |
| Drug |
cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone |
1 |
2012 |
| Drug |
cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone/prednisolone (chop) |
1 |
2012 |
| Drug |
cyclophosphamide, vincristine, prednisone |
1 |
2012 |
| Drug |
cyclophosphamide, vincristine, prednisone, dacarbazine |
1 |
2015 |
| Drug |
cyclophosphamide, vincristine, prednisone/prednisolone (cvp) |
1 |
2012 |
| Drug |
cyclophosphamide/fludarabine lymphodepleting chemotherapy |
1 |
2019 |
| Drug |
cyclophosphamide/total body irradiation |
1 |
2011 |
| Drug |
cyclophosphamide; fludarabine; cyclosporin; campath-1h (alemtuzumab); gm-csf |
1 |
2007 |
| Drug |
cyclosporin-a |
1 |
2007 |
| Drug |
cyclosporine a |
1 |
2013 |
| Drug |
cyclosporine a (csa) |
1 |
2007 |
| Drug |
cyclosporine ophthalmic emulsion |
1 |
2008 |
| Biological |
cycolophosphamide, vacristine, |
1 |
2012 |
| Biological |
cycolophosphamide, vacristine,/pednisone (cvp) x6 cycles followed by tositumomab/iodine i 131 tositumomab. |
1 |
2012 |
| Drug |
cyproheptadine hydrochloride |
1 |
2003 |
| Drug |
cyt-0851 |
1 |
2019 |
| Drug |
cytarabine (ara-c) |
1 |
1999 |
| Drug |
cytarabine ara-c |
1 |
2007 |
| Drug |
cytarabine injection |
1 |
2019 |
| Drug |
cytarabine, leucovorin, methotrexate, procarbazine, rituximab, vincristine |
1 |
2008 |
| Other |
cytogenetic analysis |
1 |
2010 |
| Procedure |
cytogenetic analysis of bone marrow specimen |
1 |
2007 |
| Biological |
cytokine-treated veto cells |
1 |
2018 |
| Other |
cytokine assessment |
1 |
2010 |
| Other |
cytology specimen collection procedure |
1 |
2015 |
| Drug |
cytosine arabinoside |
1 |
2005 |
| Drug |
cz48 |
1 |
2015 |
| Drug |
da-epoch |
1 |
2019 |
| Drug |
da-epoch-r followed by nivolumab |
1 |
2018 |
| Drug |
da-epoch-r for dlbcl, ptld, |
1 |
2012 |
| Drug |
da-epoch-r for dlbcl, ptld,/pmbcl |
1 |
2012 |
| Drug |
dabrafenib |
1 |
2015 |
| Drug |
dacarbazine(r) |
1 |
2013 |
| Biological |
dactinomycin |
1 |
1999 |
| Drug |
daratumumab/rhuph20 |
1 |
2019 |
| Drug |
darinaparsin |
1 |
2007 |
| Drug |
dasatinib (bms-354825) |
1 |
2006 |
| Drug |
dasatinib maximum tolerated dose |
1 |
2007 |
| Drug |
daunomycin |
1 |
2005 |
| Drug |
daunorubicin (dnr) |
1 |
2016 |
| Drug |
day |
1 |
2011 |
| Drug |
day iv on days -2,-1 |
1 |
2016 |
| Drug |
day iv on days -5,-4 |
1 |
2016 |
| Drug |
day iv on days -6, -5 |
1 |
2016 |
| Drug |
dbvd chemotherapy regimen |
1 |
2015 |
| Biological |
dc |
1 |
2013 |
| Drug |
dcds0780a |
1 |
2015 |
| Drug |
dcdt2980s |
1 |
2010 |
| Drug |
debio 0932 |
1 |
2010 |
| Drug |
debio 1143 (at-406) |
1 |
2010 |
| Drug |
debio 1562 |
1 |
2015 |
| Drug |
deca |
1 |
2013 |
| Drug |
defactinib |
1 |
2015 |
| Drug |
deferasirox |
1 |
2011 |
| Radiation |
definitive intensity-modulated radiotherapy (imrt) |
1 |
2020 |
| Other |
demographic variables |
1 |
2008 |
| Biological |
dendritic cell therapy |
1 |
2017 |
| Biological |
dendritic cell vaccine therapy |
1 |
2010 |
| Biological |
denileukin diftitox (e7777) |
1 |
2011 |
| Drug |
denosumab |
1 |
2009 |
| Drug |
deoxycoformycin (dcf) |
1 |
2002 |
| Drug |
deoxycytidine |
1 |
2000 |
| Procedure |
depleted haploidentical hsct |
1 |
2015 |
| Drug |
depocyteâ® |
1 |
2006 |
| Other |
detection of kir receptor by rt pcr |
1 |
2008 |
| Drug |
dexabeam |
1 |
2014 |
| Drug |
dexametasone |
1 |
2008 |
| Drug |
dexamethasone acetate |
1 |
2011 |
| Drug |
dexamethasone, cytarabine, etoposide, pegylated-asparaginase |
1 |
2016 |
| Drug |
dexamethasone, vindesine, methotrexate, ifosfamide, daunorubicin, pegylated-asparaginase |
1 |
2016 |
| Drug |
dexamethasone,vincristine, pegylated-asparaginase, cytarabine, cyclophosphamide, doxorubicin, 6-mercaptopurine |
1 |
2016 |
| Drug |
dexamethasone,vincristine, pegylated-asparaginase, cytarabine, cyclophosphamide, methotrexate |
1 |
2016 |
| Drug |
dextromethorphan hydrobromide |
1 |
1999 |
| Drug |
di-leu16-il2 |
1 |
2014 |
| Biological |
di-leu16-il2 immunocytokine |
1 |
2008 |
| Dietary Supplement |
dietary intervention |
1 |
2009 |
| Other |
digital polymerase chain reaction |
1 |
2016 |
| Drug |
dimethylfumarate |
1 |
2015 |
| Biological |
diphtheria toxoid |
1 |
2015 |
| Biological |
diphtheria toxoid/tetanus toxoid/acellular pertussis vaccine adsorbed |
1 |
2015 |
| Genetic |
dli |
1 |
2011 |
| Drug |
dms 612 |
1 |
2009 |
| Drug |
dnr |
1 |
2014 |
| Drug |
dolastatin 10 |
1 |
2000 |
| Biological |
donor natural killer cell infusion |
1 |
2009 |
| Other |
donor search prognosis score |
1 |
2019 |
| Biological |
dose-escalation stage |
1 |
2011 |
| Drug |
dose dense abvd |
1 |
2014 |
| Biological |
double umbilical cord blood transplant |
1 |
2012 |
| Drug |
doxo |
1 |
2015 |
| Drug |
doxorubicin (adriamycin) |
1 |
2005 |
| Drug |
doxorubicin 50 mg |
1 |
2008 |
| Drug |
doxorubicin 50 mg/m^2 |
1 |
2008 |
| Drug |
doxorubicin hcl |
1 |
2013 |
| Drug |
doxorubicin hydrochloride (dox) |
1 |
1999 |
| Drug |
doxorubicin liposome, with |
1 |
2019 |
| Drug |
doxorubicin pegylated |
1 |
2007 |
| Drug |
doxorubicin, cotrimoxazole, carboplatin, ifosfamide, dexamethasone, prednisone, vincristine, cytarabine, methotrexate, etoposide, cyclophosphamide, vinblastine |
1 |
2005 |
| Drug |
doxorubicin, rituxan, cyclophosphamide, vincristine |
1 |
2005 |
| Drug |
doxorubicin, rituxan, cyclophosphamide, vincristine/prednisone |
1 |
2005 |
| Drug |
doxorubicin. |
1 |
2018 |
| Drug |
doxycycline |
1 |
2013 |
| Drug |
doxycycline (tetracycline) |
1 |
2009 |
| Drug |
doxycycline monohydrate |
1 |
2014 |
| Biological |
dpx-survivac |
1 |
2017 |
| Biological |
drl_ri (proposed rituximab biosimilar) |
1 |
2019 |
| Drug |
drug: carfilzomib |
1 |
2010 |
| Drug |
ds-3078a |
1 |
2012 |
| Drug |
ds-3201b |
1 |
2016 |
| Drug |
ds-8273a |
1 |
2014 |
| Drug |
dtrm-505 |
1 |
2016 |
| Drug |
dual specificity cd19 |
1 |
2018 |
| Drug |
dual specificity cd19/cd22 car-t cell immunotherapy |
1 |
2018 |
| Drug |
durvalumab; medi4736 |
1 |
2016 |
| Drug |
e7766 |
1 |
2019 |
| Drug |
e7777 |
1 |
2016 |
| Drug |
e7777 9 mcg |
1 |
2013 |
| Drug |
e7777 9 mcg/kg |
1 |
2013 |
| Drug |
e7820 |
1 |
2004 |
| Other |
early interim fdg pet |
1 |
2011 |
| Other |
early interim fdg pet/ct after 1 cycle of r-chop |
1 |
2011 |
| Biological |
ebna1 c-terminal |
1 |
2010 |
| Biological |
ebna1 c-terminal/lmp2 chimeric protein-expressing recombinant modified vaccinia ankara vaccine |
1 |
2010 |
| Biological |
ebv-ctls |
1 |
2008 |
| Biological |
ebv-specific t cells |
1 |
2011 |
| Biological |
ebv-specific t cells: a |
1 |
2012 |
| Biological |
ebv-specific t cells: b |
1 |
2012 |
| Drug |
ebv ctl’s |
1 |
2014 |
| Biological |
ebvint cell |
1 |
2018 |
| Biological |
ebvst cells |
1 |
2016 |
| Drug |
ecp |
1 |
2005 |
| Drug |
ecp with 5-aminolevulinic acid |
1 |
2017 |
| Drug |
efavirenz |
1 |
2012 |
| Drug |
efficacy of lcar-t2c car-t cells |
1 |
2019 |
| Procedure |
electroacupuncture therapy |
1 |
2002 |
| Drug |
elsamitrucin |
1 |
2004 |
| Drug |
elsamitrusin |
1 |
2005 |
| Biological |
emd 521873 |
1 |
2009 |
| Drug |
enalapril |
1 |
2010 |
| Drug |
enalapril/carvedilol |
1 |
2010 |
| Drug |
entecavir prophylaxis |
1 |
2009 |
| Dietary Supplement |
enterade |
1 |
2016 |
| Drug |
entospletinib sdd |
1 |
2013 |
| Drug |
enzalutamide |
1 |
2015 |
| Drug |
enzastaurin hydrochloride |
1 |
2017 |
| Drug |
enzyme inhibitor therapy |
1 |
2017 |
| Drug |
epacadostat |
1 |
2017 |
| Drug |
epirubicin hydrochloride |
1 |
2003 |
| Drug |
epirubicin injectable product |
1 |
2016 |
| Drug |
epoch-rr |
1 |
2010 |
| Drug |
epoch ii |
1 |
1999 |
| Drug |
equivalent |
1 |
2007 |
| Drug |
eribulin mesylate |
1 |
2014 |
| Drug |
erk inhibitor onc201 |
1 |
2015 |
| Drug |
erwinaseâ® |
1 |
2017 |
| Drug |
erwinia asparaginase |
1 |
2011 |
| Drug |
erythropoietin beta |
1 |
2006 |
| Drug |
escalated beacopp |
1 |
2011 |
| Drug |
esomeprazole |
1 |
2013 |
| Biological |
et019003-t cells |
1 |
2019 |
| Biological |
et190l1-artemisâ„¢ t cells - iv high dose |
1 |
2019 |
| Biological |
et190l1-artemisâ„¢ t cells -iv low dose |
1 |
2019 |
| Biological |
et190l1-artemisâ„¢ t cells -iv middle dose |
1 |
2019 |
| Biological |
et190l1 artemisâ„¢ t cells |
1 |
2018 |
| Biological |
etaracizumab |
1 |
2002 |
| Drug |
etoposide (bucye regimen) |
1 |
2009 |
| Drug |
etoposide (conditioning for auto transplant) |
1 |
2010 |
| Drug |
etoposide capsule |
1 |
2018 |
| Drug |
etoposide, carboplatin, ifosfamide |
1 |
2008 |
| Drug |
etoposide, carmustine |
1 |
2008 |
| Drug |
etopside |
1 |
2016 |
| Drug |
everolimus (rad001) |
1 |
2009 |
| placebo |
everolimus placebo |
1 |
2008 |
| Drug |
everolimus/rituximab |
1 |
2011 |
| Drug |
everolmus |
1 |
2008 |
| Other |
ex-vivo umbilical cord blood expansion |
1 |
2006 |
| Drug |
exatecan mesylate |
1 |
2000 |
| Drug |
exemestane |
1 |
2015 |
| Behavioral |
exercise intervention |
1 |
2009 |
| Radiation |
experimental arm |
1 |
2016 |
| Other |
external beam radiotherapy |
1 |
2005 |
| Other |
external beam radiotherapy/90-y ibritumomab tiuxetan |
1 |
2005 |
| Drug |
famotidine |
1 |
2018 |
| Other |
fatigue inventory |
1 |
2010 |
| Procedure |
fcm |
1 |
2006 |
| Procedure |
fdg-pet scan |
1 |
2007 |
| Drug |
fenretinide lipid matrix |
1 |
2007 |
| Drug |
feraheme |
1 |
2013 |
| Dietary Supplement |
ferrous sulfate |
1 |
2008 |
| Drug |
ff-10502-01 |
1 |
2016 |
| Other |
fiau-pet-ct-2 |
1 |
2009 |
| Other |
fiau-pet-ct-4 |
1 |
2009 |
| Drug |
filgrastim 0.3 mg |
1 |
2019 |
| Drug |
filgrastim 0.3 mg/ml |
1 |
2019 |
| Drug |
filgrastim sd |
1 |
2002 |
| Drug |
filgrastim sd/01 |
1 |
2002 |
| Drug |
fimepinostat |
1 |
2012 |
| Drug |
first line chemotherapy |
1 |
2007 |
| Diagnostic Test |
fish |
1 |
2018 |
| Drug |
fixed dose plerixafor |
1 |
2010 |
| Drug |
flavopiridol |
1 |
2007 |
| Diagnostic Test |
flow-mrd |
1 |
2018 |
| Diagnostic Test |
flow immunophenotyping |
1 |
2018 |
| Drug |
flt3l |
1 |
2018 |
| Drug |
flu-mel |
1 |
2008 |
| Drug |
fluconazole |
1 |
2016 |
| Drug |
fludarabine (conditioning for allo transplant) |
1 |
2010 |
| Drug |
fludarabine (flu) |
1 |
2018 |
| Drug |
fludarabine 25 mg |
1 |
2011 |
| Drug |
fludarabine 25 mg/mâ² d 1-3 / rituximab 375 mg/mâ² d 1 q4w |
1 |
2011 |
| Drug |
fludarabine lymphodepleting chemotherapy |
1 |
2019 |
| Drug |
fludarabine monophosphate |
1 |
2012 |
| Other |
fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft |
1 |
2008 |
| Drug |
fludarabine/ melphalan |
1 |
2011 |
| Drug |
fludarabine/cyclophosphamide |
1 |
2017 |
| Drug |
fludarabine/melphalan |
1 |
2011 |
| Procedure |
fludeoxyglucose f 18 positron-emission tomography (pet) scan |
1 |
2004 |
| Radiation |
fludeoxyglucose f18 |
1 |
2009 |
| Device |
fluorine-18 fluorodeoxyglucose positron emission tomography (18f-fdg-pet) |
1 |
2015 |
| Drug |
fm |
1 |
2009 |
| Drug |
fm/r |
1 |
2009 |
| Biological |
follicular lymphoma |
1 |
2006 |
| Biological |
follicular lymphoma, patient-specific, soluble protein idiotype vaccine |
1 |
2007 |
| Drug |
folotyn |
1 |
2014 |
| Drug |
folotyn/leucovorin |
1 |
2014 |
| Drug |
forodesine 200 mg |
1 |
2007 |
| Drug |
fostamatinib disodium |
1 |
2008 |
| Drug |
fractionated iced |
1 |
2015 |
| Drug |
fragmin |
1 |
2000 |
| Drug |
ft596 |
1 |
2020 |
| Drug |
fvd regimen |
1 |
2013 |
| Drug |
g-csf (filgrastim, neupogen (r)) combination |
1 |
2006 |
| Drug |
g-csf followed by beam |
1 |
2008 |
| Drug |
g-csf, |
1 |
2008 |
| Drug |
ga 101 |
1 |
2016 |
| Drug |
gamma-secretase |
1 |
2010 |
| Drug |
gamma-secretase/notch signalling pathway inhibitor ro4929097 |
1 |
2010 |
| Biological |
ganitumab |
1 |
2007 |
| Drug |
gazyvaro |
1 |
2017 |
| Drug |
gcsf |
1 |
2013 |
| Biological |
gd2 |
1 |
2020 |
| Drug |
gdc-0032 |
1 |
2011 |
| Drug |
gdc-0199 |
1 |
2015 |
| Drug |
gdc-0349 |
1 |
2011 |
| Drug |
gdc-0425 |
1 |
2011 |
| Drug |
gdc-0575 |
1 |
2012 |
| Drug |
gdc-0853 |
1 |
2013 |
| Drug |
gdc-0917 |
1 |
2010 |
| Drug |
gdc-0941 |
1 |
2009 |
| Drug |
gdp chemotherapy |
1 |
2014 |
| Drug |
gdp chemotherapy regimen |
1 |
2015 |
| Drug |
gdpt regimen |
1 |
2012 |
| Drug |
gelad |
1 |
2016 |
| Drug |
gemcitabin |
1 |
2020 |
| Drug |
gemcitabine-oxaliplatin |
1 |
2005 |
| Drug |
gemcitabine-oxaliplatin/rituximab (r-gemox) |
1 |
2005 |
| Drug |
gemcitabine - 21 day cycle |
1 |
2018 |
| Drug |
gemcitabine - 28 day cycle |
1 |
2018 |
| Drug |
gemcitabine / oxaliplatin |
1 |
2019 |
| Drug |
gemcitabine / rituximab |
1 |
2011 |
| Drug |
gemcitabine 500 mg |
1 |
2017 |
| Drug |
gemcitabine 700 mg |
1 |
2017 |
| Drug |
gemcitabine hcl oral formulation |
1 |
2013 |
| Drug |
gemcitabine, irinotecan, allopurinol. |
1 |
2006 |
| Drug |
gemcitabine, vinorelbine, filgastrim |
1 |
2005 |
| Drug |
gemcitabine, vinorelbine, ifosfamide, filgastrim |
1 |
2005 |
| Drug |
gemcitabine, vinorelbine/doxorubicin liposome, with/without rituximab |
1 |
2019 |
| Drug |
gemcitabine/oxaliplatin |
1 |
2012 |
| Drug |
gemcitabine/plitidepsin |
1 |
2008 |
| Drug |
gemox |
1 |
2015 |
| Drug |
gen3009 |
1 |
2020 |
| Biological |
gen3013 (duobodyâ®-cd3xcd20) |
1 |
2018 |
| Drug |
generic = plerixafor |
1 |
2009 |
| Biological |
geptanolimab injection 10mg |
1 |
2017 |
| Biological |
geptanolimab injection 10mg/kg |
1 |
2017 |
| Biological |
geptanolimab injection 10mg/kg, , q2w*6 |
1 |
2017 |
| Biological |
geptanolimab injection 1mg |
1 |
2017 |
| Biological |
geptanolimab injection 1mg/kg |
1 |
2017 |
| Biological |
geptanolimab injection 1mg/kg, q2w*6 |
1 |
2017 |
| Biological |
geptanolimab injection 280mg, q3w |
1 |
2017 |
| Biological |
geptanolimab injection 3mg |
1 |
2017 |
| Biological |
geptanolimab injection 3mg/kg |
1 |
2017 |
| Biological |
geptanolimab injection 3mg/kg, q2w |
1 |
2017 |
| Biological |
geptanolimab injection 3mg/kg, q2w*6 |
1 |
2017 |
| Behavioral |
geriatric assessment |
1 |
2013 |
| Drug |
glide |
1 |
2017 |
| Drug |
gls-010 |
1 |
2018 |
| Drug |
glucarpidase |
1 |
2008 |
| Drug |
glutamic acid |
1 |
2006 |
| Drug |
go-203-2c |
1 |
2011 |
| Drug |
golimumab |
1 |
2013 |
| Drug |
goserelin |
1 |
2009 |
| Drug |
granisetron |
1 |
2007 |
| Drug |
granisetron hydrochloride |
1 |
2006 |
| Drug |
granulocyte-colony-stimulating factor |
1 |
2007 |
| Drug |
granulocyte-colony stimulating factor |
1 |
2011 |
| Drug |
granulocyte-macrophage colony stimulating factor (gm-csf) |
1 |
1999 |
| Drug |
granulocyte colony-stimulating factor |
1 |
2005 |
| Drug |
granulocyte colony-stimulating factor/placebo |
1 |
2005 |
| Drug |
granulocyte colony-stimulating factor/plerixafor |
1 |
2005 |
| Drug |
gs-4059 |
1 |
2012 |
| Drug |
gs-5829 |
1 |
2015 |
| Drug |
gsk3326595 |
1 |
2016 |
| Drug |
gsk461364 |
1 |
2007 |
| Drug |
gvd chemotherapy |
1 |
2017 |
| Drug |
gwn323 |
1 |
2016 |
| Drug |
gz17-6.02 |
1 |
2018 |
| Drug |
ha20-humanized anti-cd20 antibody |
1 |
2006 |
| Drug |
half cyclophosphamide |
1 |
2005 |
| Biological |
haploidentical bone marrow transplant |
1 |
2012 |
| Biological |
haploidentical bone marrow transplantation |
1 |
2009 |
| Device |
haploidentical natural killer cell infusion |
1 |
2014 |
| Drug |
hd- methotrexate (mtx) |
1 |
2014 |
| Drug |
hd-arac |
1 |
2011 |
| Drug |
hd-mtx |
1 |
2011 |
| Drug |
hd-mtx-ara-c regimen |
1 |
2013 |
| Drug |
hdarac |
1 |
2005 |
| Other |
hdt |
1 |
2011 |
| Other |
healthy living control |
1 |
2019 |
| Procedure |
hematopoietic cell transplant |
1 |
2015 |
| Drug |
hematopoietic stem cell rescue |
1 |
2009 |
| Procedure |
hematopoietic stem cell transplantation |
1 |
2007 |
| Biological |
hematopoietic umbilical cord blood stem cell transplantation |
1 |
2009 |
| Drug |
hexal |
1 |
2017 |
| Drug |
high-dose chemotherapy |
1 |
2010 |
| Drug |
high-dose cyclophosphamide |
1 |
2005 |
| Drug |
high-dose cytarabine (hidac) |
1 |
2015 |
| Procedure |
high dose chemo then auto hematopoietic cell transplant |
1 |
2005 |
| Drug |
high dose chemotherapy before allogeneic stem cell transplantation (allosct) |
1 |
2019 |
| Other |
high dose chemotherapy with autologous stem cell transplant followed by maintenance therapy with romidepsin |
1 |
2013 |
| Drug |
high dose cytarabine |
1 |
2005 |
| Drug |
high dose il-2 |
1 |
2019 |
| Drug |
high dose methotrexate |
1 |
2005 |
| Drug |
high dose methylprednisolone (hdmp) |
1 |
2011 |
| Drug |
high dose mtx |
1 |
2009 |
| Drug |
high dose of methotrexate |
1 |
2013 |
| Procedure |
high dose therapy |
1 |
2008 |
| Procedure |
high dose therapy/autologous stem cell transplantation |
1 |
2008 |
| Procedure |
high frequency ultrasound imaging |
1 |
2005 |
| Drug |
high risk with complete early response after 1 abvd |
1 |
2018 |
| Drug |
high risk with complete early response after 1 abvd/1 eshap courses. four more chemotherapy courses are delivered alternating eshap/abvd. |
1 |
2018 |
| Drug |
high risk with partial remission after 1 abvd |
1 |
2018 |
| Drug |
high risk with partial remission after 1 abvd/1 eshap courses. six more chemotherapy courses are delivered alternating eshap/abvd. |
1 |
2018 |
| Drug |
highly active antiretroviral therapy |
1 |
2007 |
| Drug |
hmpl-523 |
1 |
2018 |
| Procedure |
hpc(a) stem cell allograft |
1 |
2018 |
| Drug |
hs006 |
1 |
2018 |
| Drug |
hs006/chop |
1 |
2018 |
| Biological |
hsc835 |
1 |
2011 |
| Procedure |
hsct |
1 |
2011 |
| Biological |
hsct with non-tbi regimen |
1 |
2017 |
| Biological |
hsct with tbi regimen |
1 |
2017 |
| Biological |
hu14.18k322a |
1 |
2014 |
| Biological |
hucart19 |
1 |
2015 |
| Procedure |
human anti-human antibodies |
1 |
2009 |
| Other |
human blood sample |
1 |
2017 |
| Drug |
human cd19 targeted t cells injection |
1 |
2018 |
| Biological |
human myeloid progenitor cells |
1 |
2009 |
| Drug |
hydroxyurea |
1 |
1999 |
| Drug |
hyper-cvad |
1 |
2010 |
| Radiation |
hyperfractionated total body irradiation |
1 |
2018 |
| Radiation |
hypofractionated index site radiation |
1 |
2018 |
| Drug |
hz-a-018 |
1 |
2019 |
| Drug |
i-131 tositumomab therapeutic regimen |
1 |
2007 |
| Biological |
î² |
1 |
2019 |
| Drug |
ibi376 |
1 |
2020 |
| Drug |
ibritumomab tiuxetan (zevalinâ®) |
1 |
2005 |
| Drug |
ibritumomab tiuxetan / maintenance |
1 |
2013 |
| Drug |
ibrutinib-rice |
1 |
2016 |
| Drug |
ibrutinib (arm 1 - closed with amendment g) |
1 |
2014 |
| Drug |
ibrutinib (arms 2 |
1 |
2014 |
| Drug |
ibrutinib (arms 2/3) |
1 |
2014 |
| Drug |
ibrutinib (induction) |
1 |
2016 |
| Drug |
ibrutinib (maintenance) |
1 |
2016 |
| Drug |
ibrutinib / ga101 /gdc-0199 |
1 |
2015 |
| Drug |
ibrutinib 420 mg |
1 |
2017 |
| Drug |
ibrutinib 560 mg |
1 |
2017 |
| Drug |
ibrutinib oral capsule [imbruvica] |
1 |
2017 |
| Drug |
ibrutinib/bortezomib / r-chop |
1 |
2017 |
| Biological |
ic9-car19 t cells |
1 |
2018 |
| Biological |
icar19 car-t cells |
1 |
2017 |
| Biological |
icar30 t cells |
1 |
2017 |
| Drug |
ice chemotherapy |
1 |
2017 |
| Biological |
id-klh |
1 |
2007 |
| Drug |
idarubicin, methotrexate, filgrastim, intrathecal ara-c |
1 |
2005 |
| Drug |
idasanutlin |
1 |
2017 |
| Drug |
idec-c2b8 |
1 |
2014 |
| Drug |
idelalisib 100 mg |
1 |
2017 |
| Biological |
idiotype vaccine |
1 |
2000 |
| Drug |
ifosfamid |
1 |
2011 |
| Drug |
ifosfamide / mesna |
1 |
2005 |
| Drug |
ifosfamide, etoposide, cytarabine, |
1 |
2017 |
| Drug |
ifosfamide, etoposide, cytarabine,/methotrexate (ivam) chemotherapy |
1 |
2017 |
| Drug |
igg-rfb4-smpt-dga |
1 |
1999 |
| Drug |
igm-2323 |
1 |
2019 |
| Biological |
il-15 |
1 |
2016 |
| Biological |
il-15/alemtuzumab |
1 |
2016 |
| Drug |
im156 |
1 |
2017 |
| Drug |
imbruvica |
1 |
2015 |
| Biological |
imc-002 |
1 |
2020 |
| Drug |
imetelstat sodium |
1 |
2011 |
| Drug |
imexon |
1 |
2011 |
| Drug |
imgn529 |
1 |
2012 |
| Procedure |
immunochemotherapy, in vivo purging |
1 |
2006 |
| Procedure |
immunochemotherapy, in vivo purging/autrotransplant |
1 |
2006 |
| Procedure |
immunotherapy |
1 |
2007 |
| Procedure |
immunotoxin therapy |
1 |
2005 |
| Drug |
imo-8400 |
1 |
2014 |
| Drug |
imprime pgg |
1 |
2014 |
| Radiation |
imrt |
1 |
2016 |
| Radiation |
in-rt 30 gy ( |
1 |
2007 |
| Radiation |
in-rt 30 gy (/ boost 6 gy residual) |
1 |
2007 |
| Drug |
in-zevalin |
1 |
2008 |
| Radiation |
in 30gy rt in case of pr at the end of chemotherapy |
1 |
2018 |
| Procedure |
in vitro-treated peripheral blood stem cell transplantation (pbsct) |
1 |
2000 |
| Drug |
in zevalin |
1 |
2012 |
| Biological |
inactivated influenza vaccine |
1 |
2018 |
| Drug |
incb050465 |
1 |
2018 |
| Drug |
incb053914 |
1 |
2018 |
| Drug |
incb7839 |
1 |
2014 |
| Biological |
indium-111 ibritumomab tiuxetan |
1 |
2003 |
| Radiation |
indium 111 ibritumomab tiuxetan |
1 |
2006 |
| Radiation |
indium in 111-dota-biotin |
1 |
2015 |
| Biological |
indium in 111 anti-cd45 monoclonal antibody bc8 |
1 |
2012 |
| Radiation |
indium in 111 ll2 igg |
1 |
1999 |
| Radiation |
indium in 111 monoclonal antibody mn-14 |
1 |
1999 |
| Behavioral |
individualized yoga intervention group |
1 |
2014 |
| Drug |
induction |
1 |
2015 |
| Procedure |
induction treatment part 1 |
1 |
2007 |
| Procedure |
induction treatment part 2 with pbpc collection |
1 |
2007 |
| Procedure |
induction treatment part 3 |
1 |
2007 |
| Drug |
induction venetoclax |
1 |
2017 |
| Drug |
infliximab |
1 |
2013 |
| Biological |
influenza vaccination with influenza vaccine |
1 |
2012 |
| Other |
informational intervention |
1 |
2008 |
| Procedure |
infusion of non-t-cell depleted bone marrow on day 0 |
1 |
2016 |
| Biological |
injection of ebv specific ctls |
1 |
2003 |
| Drug |
injection of filgrastim |
1 |
2008 |
| Drug |
injection of pegfilgrastim |
1 |
2008 |
| Drug |
inotuzumab ozogamicin [cmc-544] |
1 |
2003 |
| Drug |
inotuzumab ozogamicin/rituximab /cyclophosphamide/vincristine/prednisone |
1 |
2010 |
| Drug |
inotuzumab ozogamicin/rituximab/gemcitabine/cisplatinum/dexamethasone |
1 |
2010 |
| Radiation |
intensity-modulated radiation therapy |
1 |
2014 |
| Radiation |
intensity modulated radiation plan |
1 |
2009 |
| Drug |
intensive chemotherapy |
1 |
2009 |
| Drug |
intensive chemotherapy/hematopoietic stem cell rescue |
1 |
2009 |
| Procedure |
intensive induction-bmt |
1 |
2007 |
| Drug |
interferon-a-2a |
1 |
2012 |
| Drug |
interferon-alfa-2b |
1 |
2016 |
| Procedure |
interim pet |
1 |
2013 |
| Procedure |
interim therapy scintigraphy study gallium scan |
1 |
2006 |
| Procedure |
interim therapy scintigraphy study gallium scan/pet/ct |
1 |
2006 |
| Biological |
interleukin |
1 |
2019 |
| Drug |
interleukin-1 |
1 |
1999 |
| Biological |
interleukin-7/chemokine (c-c motif) ligand 19-expressing cd19-car-t cells |
1 |
2019 |
| Drug |
intermediate risk with complete early response after two cycles of abvd chemotherapy schedule. three more abvd courses are delivered. |
1 |
2018 |
| Drug |
intermediate risk with partial remission after two cycles of abvd chemotherapy schedule. four more chemotherapy courses are delivered alternating eshap |
1 |
2018 |
| Drug |
intermediate risk with partial remission after two cycles of abvd chemotherapy schedule. four more chemotherapy courses are delivered alternating eshap/abvd. |
1 |
2018 |
| Other |
intervention by caregiver |
1 |
2010 |
| Biological |
intranodal injection of ad-isf35 |
1 |
2009 |
| Drug |
intrathecal (it) |
1 |
2015 |
| Drug |
intrathecal cytarabine |
1 |
1999 |
| Procedure |
intrathecal injection |
1 |
2018 |
| Drug |
intrathecal prophylaxis |
1 |
2005 |
| Drug |
intravenous |
1 |
2011 |
| Drug |
intravenous (iv) |
1 |
2018 |
| Drug |
intravenous (iv) sea-cd40 |
1 |
2015 |
| Drug |
intravenous (iv)/oral vitamin c |
1 |
2018 |
| Drug |
intravenous ezn-2968 (anti-hif-1î± lna as-odn) |
1 |
2007 |
| Drug |
intravenous fluids |
1 |
2019 |
| Drug |
intraventricular rituximab |
1 |
2005 |
| Drug |
intraventricular rituximab/mtx |
1 |
2005 |
| Drug |
investigator’s choice |
1 |
2005 |
| Drug |
investigator’s choice chemotherapy |
1 |
2016 |
| Drug |
investigators choice single agent |
1 |
2009 |
| Radiation |
involved-field radiation therapy |
1 |
2001 |
| Radiation |
involved-site radiation therapy (isrt) |
1 |
2013 |
| Radiation |
involved field irradiation |
1 |
2009 |
| Radiation |
involved field radiotherapy |
1 |
2009 |
| Radiation |
involved site radiation therapy |
1 |
2017 |
| Drug |
ioc |
1 |
2019 |
| Biological |
iodine-131 anti-b1 antibody (tositumomab |
1 |
2009 |
| Biological |
iodine-131 anti-b1 antibody versus anti-b1 antibody in chemotherapy-relapsed |
1 |
2012 |
| Biological |
iodine-131 anti-b1 antibody versus anti-b1 antibody in chemotherapy-relapsed/refractory low-grade/transformed low-grade non-hodgkin’s lymphoma (nhl) |
1 |
2012 |
| Biological |
iodine-131 anti-b1 antibody) |
1 |
2009 |
| Biological |
iodine-131 tositumomab |
1 |
2010 |
| Drug |
iodine i-131 tositumomab |
1 |
2013 |
| Radiation |
iodine i 131 monoclonal antibody lym-1 |
1 |
2002 |
| Biological |
iodine i 131 tositumomab (anti-b1 antibody |
1 |
2009 |
| Biological |
iodine i 131 tositumomab (anti-b1 antibody) |
1 |
2009 |
| Biological |
iodine i 131 tositumomab followed by chop |
1 |
2009 |
| Biological |
iodine i 131 tositumomab therapeutic regimen |
1 |
2005 |
| Biological |
iodine i 131 tositumomab. |
1 |
2012 |
| Biological |
iov-2001 |
1 |
2019 |
| Other |
ipad activity control group |
1 |
2014 |
| Drug |
ipatasertib |
1 |
2015 |
| Biological |
ipd1 cd19 ecar t cells |
1 |
2017 |
| Drug |
ipdr |
1 |
2010 |
| Drug |
ipgdp regimen chemotherapy |
1 |
2015 |
| Drug |
ipi-145 |
1 |
2013 |
| Drug |
ipi-145 (duvelisib) |
1 |
2014 |
| Biological |
iratumumab |
1 |
2003 |
| Procedure |
irradiation (in specific conditions) |
1 |
2005 |
| Radiation |
irradiation therapy |
1 |
2006 |
| Drug |
isatuximab sar650984 |
1 |
2018 |
| Drug |
isolex system |
1 |
2001 |
| Drug |
isophosphamide |
1 |
2007 |
| Drug |
ispinesib |
1 |
2006 |
| Drug |
istodax |
1 |
2013 |
| Drug |
it cytarabine |
1 |
2013 |
| Drug |
itf2357 |
1 |
2008 |
| Biological |
itreg |
1 |
2012 |
| Drug |
iv |
1 |
2020 |
| Drug |
iv busulfan, cyclophosphamide |
1 |
2009 |
| Drug |
iv busulfan, cyclophosphamide/etoposide (bucye regimen) |
1 |
2009 |
| Drug |
iv cisplatin |
1 |
2020 |
| Drug |
iv gemcitabine |
1 |
2020 |
| Drug |
iv l-asparaginase |
1 |
2020 |
| Drug |
iv nivolumab |
1 |
2020 |
| Drug |
iv/po dexamethasone |
1 |
2020 |
| Combination Product |
ivac |
1 |
2018 |
| Drug |
ive |
1 |
2015 |
| Drug |
ivosidenib |
1 |
2019 |
| Drug |
ixazomib 2.5 mg |
1 |
2011 |
| Drug |
ixazomib 4 mg capsule a |
1 |
2011 |
| Drug |
ixazomib 4 mg capsule b |
1 |
2011 |
| Drug |
jbh492 |
1 |
2020 |
| Biological |
jcar017 (lisocabtagene maraleucel) |
1 |
2017 |
| Biological |
jcar017 (lisocabtagene maraleucel) / ibrutinib |
1 |
2017 |
| Biological |
jcar017 (lisocabtagene maraleucel) 2-dose schedule |
1 |
2015 |
| Biological |
jcar017 (lisocabtagene maraleucel) single-dose schedule |
1 |
2015 |
| Drug |
jnj-26481585 |
1 |
2008 |
| Drug |
jnj-42756493: part 1 |
1 |
2012 |
| Drug |
jnj-42756493: part 2 |
1 |
2012 |
| Drug |
jnj-42756493: part 3 |
1 |
2012 |
| Drug |
jnj-42756493: part 4 |
1 |
2012 |
| Drug |
jnj-67856633 |
1 |
2019 |
| Biological |
js001 |
1 |
2016 |
| Dietary Supplement |
juven |
1 |
2003 |
| Drug |
ka2237 |
1 |
2016 |
| Biological |
kappa cd28 t cells |
1 |
2009 |
| Diagnostic Test |
karyotyping |
1 |
2018 |
| Drug |
kepivance (palifermin) |
1 |
2006 |
| Other |
ketogenic diet |
1 |
2019 |
| Drug |
kg iv on day |
1 |
2016 |
| Biological |
kg tru-016 |
1 |
2012 |
| Drug |
kg) |
1 |
2009 |
| Biological |
kg, , q2w*6 |
1 |
2017 |
| Biological |
kg, q2w |
1 |
2017 |
| Biological |
kg, q2w*6 |
1 |
2017 |
| Biological |
kgel vaccine |
1 |
2005 |
| Drug |
kidrolase |
1 |
2006 |
| Drug |
kn046 |
1 |
2018 |
| Drug |
kpt-330 |
1 |
2015 |
| Biological |
kw-0761 (mogamulizumab) |
1 |
2012 |
| Drug |
kw-2478 |
1 |
2007 |
| Drug |
l-778,123 |
1 |
1999 |
| Drug |
l-nmma |
1 |
2017 |
| Drug |
l-phenylalanine mustard |
1 |
2007 |
| Drug |
l19-il2 - ph i |
1 |
2016 |
| Drug |
l19-il2 at rd - ph ii |
1 |
2016 |
| Other |
laboratory correlative studies |
1 |
2007 |
| Other |
laboratory evaluations |
1 |
2015 |
| Diagnostic Test |
laboratory parameters |
1 |
2019 |
| Drug |
lam-002a |
1 |
2015 |
| Drug |
lamivudine |
1 |
2002 |
| Drug |
lansoprazole, amoxicillin, clarithromycin, metronidazole |
1 |
2014 |
| Drug |
lanzoprazole |
1 |
2018 |
| Drug |
lapatinib ditosylate |
1 |
2006 |
| Drug |
lcv |
1 |
2014 |
| Drug |
ldk378 |
1 |
2012 |
| Drug |
leap regimen |
1 |
2019 |
| Drug |
ledipasvir |
1 |
2016 |
| Drug |
ledipasvir/sofosbuvir |
1 |
2016 |
| Drug |
lee011 |
1 |
2010 |
| Drug |
lenalidomide (revlimidâ®) |
1 |
2007 |
| Drug |
lenalidomide 25mg |
1 |
2018 |
| Drug |
lenalidomide oral capsule |
1 |
2019 |
| Drug |
lenalidomide, bendamustine, rituximab |
1 |
2009 |
| Drug |
lenalidomide/dexametasone |
1 |
2008 |
| Drug |
lenalidomide/ga101 |
1 |
2012 |
| Drug |
lenalidomide/rituximab |
1 |
2013 |
| Drug |
lenalidomide/with r-chop |
1 |
2019 |
| Drug |
lenograstim |
1 |
2006 |
| Biological |
lentivirus vector ccr5 shrna |
1 |
2016 |
| Biological |
lentivirus vector ccr5 shrna/trim5alpha/tar decoy-transduced autologous cd34-positive hematopoietic progenitor cells |
1 |
2016 |
| Biological |
lentivirus vector rhiv7-shi-tar-ccr5rz-transduced hematopoietic stem |
1 |
2014 |
| Biological |
lentivirus vector rhiv7-shi-tar-ccr5rz-transduced hematopoietic stem/progenitor cells |
1 |
2014 |
| Biological |
lenzilumab |
1 |
2020 |
| Drug |
letermovir |
1 |
2019 |
| Biological |
lethally irradiated lymphoma cells with gm-csf k562 cells |
1 |
2007 |
| Drug |
letrozole |
1 |
2011 |
| Drug |
leukovorin |
1 |
2011 |
| Drug |
levofloxacin |
1 |
2000 |
| Device |
light therapy intensity 1 |
1 |
2017 |
| Device |
light therapy intensity 2 |
1 |
2017 |
| Drug |
lipegfilgrastim |
1 |
2014 |
| Drug |
liposomal ara-c |
1 |
2015 |
| Drug |
liposomal arac |
1 |
2014 |
| Drug |
liposomal doxorubicin/mitoxantrone |
1 |
2016 |
| Drug |
liposomal vincristine |
1 |
2011 |
| Drug |
liposomal vincristine sulfate |
1 |
2000 |
| Drug |
liposomial cytarabine |
1 |
2014 |
| Biological |
lirilumab |
1 |
2012 |
| Drug |
lithium carbonate |
1 |
2006 |
| Combination Product |
litt |
1 |
2019 |
| Combination Product |
litt / pembrolizumab |
1 |
2019 |
| Other |
live music |
1 |
2013 |
| Biological |
lmb-2 |
1 |
2004 |
| Drug |
lmb b |
1 |
2005 |
| Drug |
lmb c |
1 |
2005 |
| Drug |
lmp 400 |
1 |
2010 |
| Drug |
lmp 776 |
1 |
2010 |
| Biological |
lmp specific t cells |
1 |
2011 |
| Biological |
lmp1/2 ctls (alci - expansion - group a) |
1 |
2003 |
| Biological |
lmp1/2 ctls (alci - expansion group b) |
1 |
2003 |
| Biological |
lmp1/2 ctls (alci - expansion group c) |
1 |
2003 |
| Biological |
lmp1/2 ctls (alci - group a) |
1 |
2003 |
| Biological |
lmp1/2 ctls (alci - group b) |
1 |
2003 |
| Biological |
lmp1/2 ctls (alci - group c) |
1 |
2003 |
| Drug |
lmp1/2 ctls (group a) |
1 |
2013 |
| Drug |
lmp1/2 ctls (group b) |
1 |
2013 |
| Biological |
lmp2 chimeric protein-expressing recombinant modified vaccinia ankara vaccine |
1 |
2010 |
| Biological |
lmp2 ctls (alscer - group a) |
1 |
2003 |
| Biological |
lmp2 ctls (alscer - group b) |
1 |
2003 |
| Biological |
lmp2 ctls (alscer - group c) |
1 |
2003 |
| Drug |
lmp400 |
1 |
2013 |
| Drug |
lmp744 |
1 |
2017 |
| Radiation |
local radiotherapy |
1 |
2009 |
| Drug |
lonafarnib |
1 |
1999 |
| Drug |
loncastuximab tesirine/durvalumab |
1 |
2018 |
| Drug |
lonquek |
1 |
2015 |
| Drug |
low |
1 |
2019 |
| Radiation |
low-dose involved-field radiotherapy |
1 |
2015 |
| Radiation |
low-dose radiotherapy (rt) |
1 |
2001 |
| Drug |
low dose il-2 |
1 |
2019 |
| Radiation |
low dose radiation therapy (ldrt) |
1 |
2017 |
| Radiation |
low dose total body irradiation |
1 |
2009 |
| Drug |
low risk with complete early response after two cycles of abvd chemotherapy schedule. only one more abvd course is delivered. |
1 |
2018 |
| Drug |
low risk with partial remission at early response assessment after two cycles of abvd chemotherpay schedule. two abvd courses are delivered. |
1 |
2018 |
| Drug |
low risk with partial remisssion after 4 cycles of abvd chemotherapy schedule. two eshap courses are delivered. |
1 |
2018 |
| Drug |
loxo-305 |
1 |
2018 |
| Drug |
lr-eshap (lenalidomide 10 mg) |
1 |
2015 |
| Drug |
lr-eshap (lenalidomide 15 mg) |
1 |
2015 |
| Drug |
lr-eshap (lenalidomide 20 mg) |
1 |
2015 |
| Drug |
lr-eshap (lenalidomide 5 mg) |
1 |
2015 |
| Drug |
lsa4, cyclophosphamide, methotrexate, daunomycin, l-asparaginase, bcnu |
1 |
2007 |
| Drug |
lucar-20s car-t cells |
1 |
2019 |
| Biological |
lumiliximab |
1 |
2003 |
| Drug |
ly317615 |
1 |
2002 |
| Procedure |
lymph node biopsy |
1 |
2008 |
| Drug |
lymphodepleting |
1 |
2018 |
| Drug |
lymphodepleting chemotherapy |
1 |
2018 |
| Radiation |
lymphoid radiation |
1 |
2009 |
| Drug |
m2 by iv infusion |
1 |
2017 |
| Drug |
m2 di-leu16-il2 |
1 |
2013 |
| Drug |
m2 iv on days 1-2, cycles 1-6 |
1 |
2016 |
| Drug |
m2 rituximab |
1 |
2013 |
| Drug |
m7583 |
1 |
2016 |
| Drug |
mâ² d 1-3 |
1 |
2011 |
| Drug |
mâ² d 1 q4w |
1 |
2011 |
| Biological |
mabel ctls |
1 |
2014 |
| Procedure |
magnetic resonance imaging (mri) |
1 |
2013 |
| Drug |
maintenance |
1 |
2013 |
| Drug |
maintenance therapy |
1 |
2015 |
| Drug |
maintenance therapy post-hsct |
1 |
2018 |
| Drug |
maintenance venetoclax |
1 |
2017 |
| Drug |
maintenance weekly x4 |
1 |
2013 |
| Drug |
manganese chloride |
1 |
2019 |
| Drug |
mannitol |
1 |
2006 |
| Drug |
maraviroc |
1 |
2014 |
| Procedure |
marrow transplant (bmt) |
1 |
2019 |
| Other |
mass spectrometry |
1 |
2012 |
| Procedure |
massage therapy |
1 |
2010 |
| Biological |
mb-cart19.1 |
1 |
2019 |
| Biological |
mb-cart20.1 |
1 |
2018 |
| Biological |
mb-cart2019.1 dose level 1 |
1 |
2019 |
| Biological |
mb-cart2019.1 dose level 2 |
1 |
2019 |
| Drug |
mbvd (myocet |
1 |
2011 |
| Drug |
mbvd (myocet/bvd) |
1 |
2011 |
| Biological |
mc-19pd1 car-t cells |
1 |
2019 |
| Biological |
mdx-1203 |
1 |
2009 |
| Biological |
mdx-1401 |
1 |
2008 |
| Drug |
mechlorethamine |
1 |
1999 |
| Drug |
meda |
1 |
2016 |
| Drug |
medi-551 12 mg |
1 |
2014 |
| Drug |
medi-551 12 mg/kg |
1 |
2014 |
| Drug |
medi-551 2 mg |
1 |
2011 |
| Drug |
medi-551 2 mg/kg |
1 |
2011 |
| Drug |
medi-551 4 mg |
1 |
2011 |
| Drug |
medi-551 4 mg/kg |
1 |
2011 |
| Drug |
medi0680 10 mg |
1 |
2014 |
| Drug |
medi0680 10 mg/kg |
1 |
2014 |
| Drug |
medi0680 2.5 mg |
1 |
2014 |
| Drug |
medi0680 2.5 mg/kg |
1 |
2014 |
| Procedure |
mediastinal irradiation |
1 |
2005 |
| Other |
meditation therapy |
1 |
2019 |
| Procedure |
megadose of cd34 selected progenitor cells |
1 |
2002 |
| Drug |
megestrol acetate |
1 |
2003 |
| Drug |
melphalan hcl (propylene glycol-free) |
1 |
2013 |
| Drug |
mercaptopurine oral suspension |
1 |
2019 |
| Procedure |
mesenchymal stem cell transplantation |
1 |
2014 |
| Drug |
mesna (iv) |
1 |
2006 |
| Drug |
mesna (oral) |
1 |
2006 |
| Drug |
mesna (prior to auto transplant) |
1 |
2010 |
| Drug |
mesna, cisplatin, etoposide, rituximab |
1 |
2007 |
| Drug |
metformin hydrochloride |
1 |
2008 |
| Drug |
methionine |
1 |
2009 |
| Drug |
methotrexate (arm with bortezomib) |
1 |
2014 |
| Drug |
methotrexate (arm with maraviroc) |
1 |
2014 |
| Drug |
methotrexate (ivam) chemotherapy |
1 |
2017 |
| Drug |
methotrexate, 6-mercaptopurine |
1 |
2016 |
| Drug |
methoxsalen |
1 |
2005 |
| Drug |
methoxsalen/ecp |
1 |
2005 |
| Drug |
methoxyamine |
1 |
2012 |
| Drug |
methyl-prednisolone |
1 |
2007 |
| Drug |
mg4101 |
1 |
2018 |
| Biological |
mg4101(allogeneic natural killer cell) |
1 |
2018 |
| Drug |
mgta 456 infusion |
1 |
2018 |
| Drug |
micro needle array-doxorubicin (mna-d) |
1 |
2014 |
| Device |
microdevices |
1 |
2019 |
| Biological |
microtransplantation |
1 |
2019 |
| Radiation |
midle chemotherapy |
1 |
2010 |
| Drug |
mik665 |
1 |
2016 |
| Drug |
milademetan |
1 |
2013 |
| Biological |
milatuzumab |
1 |
2009 |
| Dietary Supplement |
milled seed mix |
1 |
2017 |
| Device |
miltenyi clinimacs |
1 |
2005 |
| Drug |
mini chep |
1 |
2007 |
| Drug |
mini cyve, without 3 maintenance courses |
1 |
2005 |
| Biological |
mismatched related donor natural killer cells |
1 |
2017 |
| Drug |
mitoguazone |
1 |
1999 |
| Drug |
mitoxantrone hydrochloride (dhad) |
1 |
1999 |
| Drug |
mitoxantrone hydrochloride liposome injection |
1 |
2018 |
| Drug |
miw815 |
1 |
2017 |
| Drug |
mk-1454 |
1 |
2017 |
| Drug |
mk-2118 (it) |
1 |
2017 |
| Drug |
mk-2118 (sc) |
1 |
2017 |
| Drug |
mk-3475 |
1 |
2015 |
| Biological |
mk-4280 |
1 |
2018 |
| Drug |
mk-8776 |
1 |
2008 |
| Drug |
mln4924 |
1 |
2008 |
| Drug |
mln9708 |
1 |
2014 |
| Drug |
moap |
1 |
2019 |
| Drug |
mocetinostat/brentuximab vedotin |
1 |
2015 |
| Other |
modified bfm-90 protocol |
1 |
2012 |
| Drug |
modified hyper-cvad |
1 |
2007 |
| Biological |
mogamulizumab |
1 |
2017 |
| Procedure |
molecular nanotechnology |
1 |
2018 |
| Genetic |
molecular response by pcr |
1 |
2007 |
| Biological |
monoclonal antibody a27.15 |
1 |
1999 |
| Biological |
monoclonal antibody cd19 |
1 |
1999 |
| Biological |
monoclonal antibody cd20 |
1 |
1999 |
| Biological |
monoclonal antibody e2.3 |
1 |
1999 |
| Biological |
monoclonal antibody hefi-1 |
1 |
1999 |
| Biological |
monoclonal antibody mono-dga-rfb4 |
1 |
2001 |
| Biological |
monoclonal antibody sgn-30 |
1 |
2006 |
| Drug |
mor00208 (formerly xmab 5574) |
1 |
2012 |
| Drug |
morphine sulfate |
1 |
1999 |
| Drug |
moxifloxacin 400 mg |
1 |
2012 |
| Radiation |
mr |
1 |
2018 |
| Other |
mri diffusion |
1 |
2017 |
| Biological |
mrna-2752 |
1 |
2018 |
| Biological |
mrna-2752 / durvalumab |
1 |
2018 |
| Drug |
ms-533 |
1 |
2018 |
| Drug |
mt-3724 phase 1 |
1 |
2015 |
| Drug |
mt-3724 phase 2 |
1 |
2015 |
| Drug |
mtx based chemotherapy |
1 |
2009 |
| Drug |
mtx, mvd, via |
1 |
2010 |
| Drug |
multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone |
1 |
2013 |
| Drug |
multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone/a combination of them |
1 |
2013 |
| Biological |
multitaa t cells stage |
1 |
2011 |
| Drug |
muromonab |
1 |
2007 |
| Behavioral |
music imagery |
1 |
2004 |
| Genetic |
mutation analysis |
1 |
2011 |
| Procedure |
mutation carrier screening |
1 |
2017 |
| Drug |
mycophenolate |
1 |
2011 |
| Drug |
mycophenylate mofetil |
1 |
2013 |
| Procedure |
myeloablative haploidentical stem cell transplant |
1 |
2012 |
| Procedure |
myeloid progenitor cell transplantation |
1 |
2014 |
| Drug |
nab-paclitaxel/rituximab-coated nanoparticle ar160 |
1 |
2016 |
| Drug |
nab paclitaxel |
1 |
2019 |
| Drug |
nab paclitaxel. |
1 |
2018 |
| Drug |
naloxone hydrochloride lotion, 0.5% |
1 |
2016 |
| Biological |
natural killer (nk) cell infusion |
1 |
2011 |
| Biological |
natural killer (nk) cells |
1 |
2016 |
| Biological |
natural killer cell infusion |
1 |
2012 |
| Drug |
navitoclax |
1 |
2017 |
| Drug |
nc-4016 |
1 |
2017 |
| Drug |
nelarabine injection 1000mg |
1 |
2006 |
| Drug |
nelarabine injection 1000mg/m2 |
1 |
2006 |
| Drug |
nelarabine injection 1500mg |
1 |
2006 |
| Drug |
nelarabine injection 1500mg/m2 |
1 |
2006 |
| Drug |
nelarabine injection 400mg |
1 |
2006 |
| Drug |
nelarabine injection 400mg/m2 |
1 |
2006 |
| Drug |
nelarabine injection 650mg |
1 |
2006 |
| Drug |
nelarabine injection 650mg/m2 |
1 |
2006 |
| Drug |
nelfinavir mesylate |
1 |
2010 |
| Drug |
neulasta |
1 |
2012 |
| Drug |
neupogen |
1 |
2010 |
| Other |
next generation sequencing |
1 |
2015 |
| Genetic |
ngs |
1 |
2018 |
| Combination Product |
niacin er |
1 |
2020 |
| Drug |
nicordâ® (omidubicel) |
1 |
2016 |
| Biological |
nicotinamide expanded haploidentical |
1 |
2017 |
| Biological |
nicotinamide expanded haploidentical/mismatched related donor natural killer cells |
1 |
2017 |
| Drug |
nicotine |
1 |
1999 |
| Drug |
nilotinib |
1 |
2010 |
| Drug |
nipent |
1 |
2007 |
| Drug |
nir178 |
1 |
2017 |
| Drug |
nitrogen mustard |
1 |
2006 |
| Drug |
nivolumab 40 mg in 4 ml injection |
1 |
2017 |
| Drug |
nivolumab cohort 1 |
1 |
2018 |
| Drug |
nivolumab cohort 2 |
1 |
2018 |
| Drug |
nivolumab, iv, 240 mg |
1 |
2017 |
| Drug |
nivolumab/epoch |
1 |
2018 |
| Other |
nivolumab/radiotherapy |
1 |
2018 |
| Drug |
niz985 |
1 |
2020 |
| Drug |
niz985/spartalizumab |
1 |
2020 |
| Biological |
nk cell infusion |
1 |
2006 |
| Procedure |
nk cell subsets |
1 |
2009 |
| Drug |
nk cells |
1 |
2019 |
| Biological |
nk immunotherapy |
1 |
2016 |
| Drug |
nktr-255 |
1 |
2019 |
| Biological |
nm-il-12 |
1 |
2015 |
| Biological |
nm-il-12/tsebt |
1 |
2015 |
| Other |
no dli |
1 |
2010 |
| Other |
no further treatment |
1 |
2009 |
| Other |
no intervention |
1 |
2006 |
| Other |
no music therapy |
1 |
2011 |
| Radiation |
no radiotherapy if cr at the end of chemotherapy. |
1 |
2018 |
| Other |
no systemic anticoagulant prophylaxis |
1 |
2015 |
| Dietary Supplement |
non-juven supplement |
1 |
2003 |
| Other |
non-myeloablative allogeneic (allo) transplant |
1 |
2010 |
| Procedure |
nonmyeloablative allogeneic hsct |
1 |
2008 |
| Drug |
norethisterone acetate |
1 |
2010 |
| Drug |
notch signalling pathway inhibitor ro4929097 |
1 |
2010 |
| Drug |
novantrone |
1 |
2007 |
| Drug |
npi-0052 |
1 |
2006 |
| Drug |
npi-0052 (marizomib) |
1 |
2008 |
| Drug |
npi-0052 (marizomib) / vorinostat |
1 |
2008 |
| Drug |
npi-2358 |
1 |
2006 |
| Device |
npt |
1 |
2015 |
| Drug |
nuc-7738 |
1 |
2019 |
| Genetic |
nucleic acid sequencing |
1 |
2011 |
| Drug |
nystatin |
1 |
1999 |
| Drug |
o-ice (ofatumumab, ifosfamide, carboplatin, etoposide) |
1 |
2015 |
| Drug |
o6-benzylguanine |
1 |
2009 |
| Drug |
obatoclax mesylate (gx15-070ms) |
1 |
2006 |
| Drug |
obinutuzumab (g) |
1 |
2018 |
| Drug |
obinutuzumab (ro5072759) |
1 |
2007 |
| Drug |
obinutuzumab injection [gazyva] |
1 |
2017 |
| Drug |
obinutuzumab/pixantrone |
1 |
2015 |
| Drug |
ocrelizumab |
1 |
2016 |
| Drug |
octreotide acetate |
1 |
1999 |
| Biological |
ofatumumab (this arm is closed) |
1 |
2011 |
| Other |
ofatumumab / bendamustine |
1 |
2011 |
| Drug |
ofatumumab / ice |
1 |
2009 |
| Drug |
ofatumumab/with sb-485232 |
1 |
2013 |
| Drug |
omeprazole/bortezomib |
1 |
2006 |
| Drug |
on01910 na |
1 |
2009 |
| Drug |
onalespib |
1 |
2015 |
| Drug |
oncaspar |
1 |
2012 |
| Drug |
oncovin |
1 |
2014 |
| Drug |
ono |
1 |
2012 |
| Drug |
ono/gs-4059 |
1 |
2012 |
| Drug |
ontak (denileukin difitox, dab389il-2) |
1 |
2005 |
| Drug |
ontak (denileukin diftitox) |
1 |
2005 |
| Drug |
opb-111077 |
1 |
2019 |
| Drug |
opdivo |
1 |
2017 |
| Drug |
optimised rituximab-schedule |
1 |
2011 |
| Drug |
oral 5-azacitidine |
1 |
2013 |
| Drug |
oral belinostat |
1 |
2006 |
| Drug |
oral contraceptive |
1 |
2009 |
| Other |
oral glucose tolerance test (ogtt) |
1 |
2012 |
| Procedure |
oral rinse |
1 |
2018 |
| Drug |
oral sodium phenylbutyrate |
1 |
1999 |
| Drug |
oral vitamin c |
1 |
2018 |
| Drug |
orbital radiation |
1 |
2015 |
| Drug |
osi-027 |
1 |
2008 |
| Drug |
osimertinib |
1 |
2015 |
| Drug |
ot-82 dose escalation |
1 |
2019 |
| Drug |
ot-82 dose expansion |
1 |
2019 |
| Drug |
oxaliplatin 100 mg |
1 |
2018 |
| Drug |
oxaliplatin, cytosine arabinoside, dexamethasone with rituxan (road) |
1 |
2005 |
| Drug |
oxaliplatin, prednisolone |
1 |
2010 |
| Drug |
oxaliplatine |
1 |
2012 |
| Drug |
oxidative phosphorylation inhibitor iacs-010759 |
1 |
2017 |
| Drug |
paclitaxel. |
1 |
2018 |
| Drug |
pacritinib |
1 |
2018 |
| Procedure |
pain therapy |
1 |
2001 |
| Drug |
panobinostat/bortezomib |
1 |
2009 |
| Drug |
part 1, cohort 1 |
1 |
2012 |
| Drug |
part 1, cohort 2 |
1 |
2012 |
| Drug |
part 1, cohort 3 |
1 |
2012 |
| Drug |
part 1: jnj-42756493 |
1 |
2013 |
| Drug |
part 2, cohort 1 |
1 |
2012 |
| Drug |
part 2, cohort 2 |
1 |
2012 |
| Drug |
part 2: jnj-42756493 |
1 |
2013 |
| Other |
patient derived xenograft |
1 |
2017 |
| Other |
patient observation |
1 |
2018 |
| Drug |
pazopanib |
1 |
2008 |
| Drug |
pazopanib (gw786034)(gw786034) |
1 |
2008 |
| Genetic |
pbcar0191 |
1 |
2018 |
| Genetic |
pbcar20a |
1 |
2019 |
| Procedure |
pbsc reinfusion |
1 |
2007 |
| Drug |
pci 32765 |
1 |
2011 |
| Drug |
pd-0332991 |
1 |
2007 |
| Drug |
pd-1 antibody, chidamide, lenalidomide |
1 |
2019 |
| Drug |
pd-1 antibody, chidamide, lenalidomide/etoposide |
1 |
2019 |
| Drug |
pd-1 blocking antibody, chidamide, lenalidomide |
1 |
2019 |
| Drug |
pd-1 blocking antibody, chidamide, lenalidomide/gemcitabine |
1 |
2019 |
| Drug |
pd-1 inhibitor |
1 |
2018 |
| Biological |
pd-l1 peptide |
1 |
2017 |
| Biological |
pd-l2 |
1 |
2017 |
| Biological |
pd-l2 peptide |
1 |
2017 |
| Biological |
pd-l2/pd-l1 peptide |
1 |
2017 |
| Drug |
pd1 |
1 |
2017 |
| Biological |
pd1 monoclonal antibody |
1 |
2020 |
| Biological |
pediatric multitaa t cells stage |
1 |
2011 |
| Biological |
pednisone (cvp) x6 cycles followed by tositumomab |
1 |
2012 |
| Behavioral |
pedometer-based activity monitoring after asct |
1 |
2017 |
| Drug |
peg-asp |
1 |
2014 |
| Drug |
peg asparaginase |
1 |
2019 |
| Drug |
peg intron |
1 |
2007 |
| Drug |
pegfilgrastim 12 mg |
1 |
2003 |
| Drug |
pegfilgrastim 6 mg |
1 |
2003 |
| Drug |
pegylated interferon-alfa-2b |
1 |
2016 |
| Biological |
pegylated interferon alfa |
1 |
2000 |
| Drug |
pegylated interferon î±-2b |
1 |
2020 |
| Drug |
pegylated liposomal doxorubicin |
1 |
2019 |
| Drug |
pegylated recombinant human granulocyte colony |
1 |
2019 |
| Drug |
pemetrexed disodium |
1 |
2007 |
| Drug |
penclomedine |
1 |
1999 |
| Drug |
pentamidine |
1 |
1999 |
| Drug |
pentetic acid calcium |
1 |
2001 |
| Drug |
pepc |
1 |
2005 |
| Drug |
perfosfamide |
1 |
1999 |
| Drug |
perillyl alcohol |
1 |
1999 |
| Other |
peripheral blood donor |
1 |
2014 |
| Procedure |
peripheral blood hematopoietic cell transplantation (hct) |
1 |
2017 |
| Procedure |
peripheral blood transplant |
1 |
2018 |
| Other |
personalized medicine |
1 |
2017 |
| Biological |
personalized tumor vaccine |
1 |
2017 |
| Biological |
pertuzumab |
1 |
2015 |
| Diagnostic Test |
pet-ct |
1 |
2019 |
| Diagnostic Test |
pet-ct scan |
1 |
2018 |
| Diagnostic Test |
pet-ct/ct |
1 |
2019 |
| Device |
pet-fdg brain imaging |
1 |
2015 |
| Device |
pet-fdg brain imaging/npt |
1 |
2015 |
| Device |
pet / ct |
1 |
2015 |
| Procedure |
pet scan with [18f]fluoro-2-deoxyglucose (fdg) |
1 |
2005 |
| Diagnostic Test |
pet/ct |
1 |
2018 |
| Other |
pet/ct post 2 cycles of chemotherapy |
1 |
2006 |
| Drug |
pf-05082566 |
1 |
2011 |
| Biological |
pf-05280586 |
1 |
2014 |
| Drug |
pf-06821497 |
1 |
2018 |
| Drug |
pf04518600 |
1 |
2018 |
| Other |
pharmacodynamic study |
1 |
2017 |
| Other |
pharmacodynamics |
1 |
2014 |
| Procedure |
pharmacokinetics |
1 |
2009 |
| Drug |
pharmorubicin |
1 |
2019 |
| Drug |
phase 1, cohort 1 |
1 |
2012 |
| Drug |
phase 1, cohort 2 |
1 |
2012 |
| Drug |
phase 1, cohort 3 |
1 |
2012 |
| Drug |
phase 1, cohort 4 |
1 |
2012 |
| Drug |
phase 2 |
1 |
2012 |
| Drug |
phenobarbital |
1 |
1999 |
| Drug |
phenytoin |
1 |
2005 |
| Other |
phosphate-buffered saline (pbs) |
1 |
2006 |
| Drug |
photodynamic therapy |
1 |
2013 |
| Device |
photopheresis |
1 |
2006 |
| Other |
physical activity intervention (pai) |
1 |
2019 |
| Drug |
pi3k-delta inhibitor tgr-1202 |
1 |
2016 |
| Drug |
pi3k inhibitor bkm120 |
1 |
2014 |
| Drug |
picoplatin |
1 |
2001 |
| Drug |
pinatuzumab vedotin |
1 |
2012 |
| Drug |
piperacillin-tazobactam |
1 |
1999 |
| Drug |
piperacillin sodium |
1 |
1999 |
| Drug |
pixantrone (bbr 2778) |
1 |
2003 |
| Drug |
pixantrone / rituximab |
1 |
2011 |
| Drug |
pixantrone, cyclophosphamide, vincristine, rituximab, prednisone |
1 |
2004 |
| placebo |
placebo for shape (shp-141) |
1 |
2011 |
| placebo |
placebo in combination with bendamustine |
1 |
2016 |
| Drug |
placebo in combination with bendamustine/rituximab |
1 |
2016 |
| placebo |
placebo lotion |
1 |
2016 |
| placebo |
placebo oral tablet to match venetoclax |
1 |
2017 |
| placebo |
placebo tablets |
1 |
2009 |
| placebo |
placebos (matched to 4 mg |
1 |
2012 |
| Drug |
placebos (matched to 4 mg/10 mg lenvatinib capsules). |
1 |
2012 |
| Procedure |
planar scintigraphy imaging |
1 |
2011 |
| Procedure |
plasma samples |
1 |
2006 |
| Biological |
plasmid dna vaccine therapy |
1 |
2007 |
| Drug |
platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy |
1 |
2018 |
| Drug |
platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy/autologous hematopoietic stem cell transplant (hsct) |
1 |
2018 |
| Drug |
platinum-containing salvage chemotherapy (eg, r-ice) followed by high dose therapy (eg, beam) |
1 |
2017 |
| Drug |
platinum-containing salvage chemotherapy (eg, r-ice) followed by high dose therapy (eg, beam)/autologous stem cell transplant in responders. |
1 |
2017 |
| Drug |
plerixafor (amd3100) |
1 |
2008 |
| Drug |
plerixafor (mozobil) |
1 |
2011 |
| Drug |
plerixafor / g-csf |
1 |
2011 |
| Drug |
plerixafor gz316455 |
1 |
2014 |
| Drug |
plitidepsin |
1 |
2008 |
| Drug |
plitidepsin/sorafenib |
1 |
2008 |
| Drug |
plx2853 |
1 |
2017 |
| Drug |
plx3397 |
1 |
2010 |
| Drug |
pmbcl |
1 |
2012 |
| Drug |
po dexamethasone |
1 |
2020 |
| Drug |
polatuzumab vedotin (liquid) |
1 |
2014 |
| Drug |
polatuzumab vedotin (lyophilized) |
1 |
2014 |
| placebo |
polatuzumab vedotin placebo |
1 |
2017 |
| Drug |
poly-iclc |
1 |
2013 |
| Drug |
polyamine analogue pg11047 |
1 |
2006 |
| Procedure |
positron emission tomography with radiolabeled targeting agent |
1 |
2011 |
| Drug |
post-chlorambucil therapy follow-up |
1 |
2012 |
| Drug |
post-hct cyclophosphamide 50mg |
1 |
2016 |
| Drug |
post-hct cyclophosphamide 50mg/kg iv on day/3, /4 |
1 |
2016 |
| Drug |
post-hct mesna |
1 |
2016 |
| Drug |
post-radiation therapy temozolomide |
1 |
2003 |
| Drug |
potassium iodide (ki) |
1 |
2007 |
| Drug |
pralatraxate, |
1 |
2018 |
| Drug |
pre-hct mesna on days -2 |
1 |
2016 |
| Drug |
pre-hct mesna on days -2/-1 |
1 |
2016 |
| Drug |
pre-hct mesna on days -5 |
1 |
2016 |
| Drug |
pre-hct mesna on days -5/-4 |
1 |
2016 |
| Drug |
pre-hct mesna on days -6 |
1 |
2016 |
| Drug |
pre-hct mesna on days -6/-5 |
1 |
2016 |
| Drug |
preben |
1 |
2016 |
| Drug |
prednisolone (chop) |
1 |
2012 |
| Drug |
prednisolone (cvp) |
1 |
2012 |
| Drug |
prednisolone, prednisone |
1 |
2007 |
| Drug |
prednisolone, prednisone/equivalent |
1 |
2007 |
| Drug |
prednison, vincristine, cytarabine, methotrexate, etoposide, cyclophosphamide, doxorubicin |
1 |
2005 |
| Drug |
prednisone (chop) |
1 |
2001 |
| Drug |
prednisone (or equivalent) |
1 |
2013 |
| Drug |
prednisone (p)) chemotherapy |
1 |
2006 |
| Drug |
prednisone 1 |
1 |
2008 |
| Drug |
prednisone 100 mg |
1 |
2008 |
| Drug |
prednisone 100 mg/m^2 |
1 |
2008 |
| Drug |
prednisone 2 |
1 |
2008 |
| Drug |
prednisone tablets |
1 |
2016 |
| Drug |
prednisone,vincristine, pegylated-asparaginase, cytarabine, cyclophosphamide, daunorubicin, 6-mercaptopurine |
1 |
2016 |
| Drug |
prednisone/prednisolone/methylprednisolone |
1 |
2019 |
| Drug |
pro95780 |
1 |
2007 |
| Drug |
procarbacine |
1 |
2006 |
| Drug |
procrit (epoetin alfa) |
1 |
2010 |
| Biological |
progenitor cells |
1 |
2014 |
| Procedure |
prophylactic intrathecal chemotherapy |
1 |
2011 |
| Drug |
prophylaxis of opportunistic infections |
1 |
2007 |
| Drug |
prophylaxis of opportunistic infections/support treatment |
1 |
2007 |
| Drug |
propofol-fentanyl |
1 |
2005 |
| Drug |
propofol alone |
1 |
2005 |
| Drug |
proteasome-inhibitor regimen |
1 |
2018 |
| Genetic |
protein expression analysis |
1 |
2007 |
| Genetic |
proteomic profiling |
1 |
2003 |
| Other |
proteosome inhibition assessment |
1 |
2010 |
| Drug |
protocol m |
1 |
2015 |
| Radiation |
proton radiation plan |
1 |
2009 |
| Drug |
prt543 |
1 |
2019 |
| Drug |
ps341 (bortezomib) |
1 |
2002 |
| Biological |
psma |
1 |
2020 |
| Drug |
psoralen |
1 |
2000 |
| Drug |
pu-h71 |
1 |
2011 |
| Drug |
px-478 |
1 |
2007 |
| Drug |
pxd101 |
1 |
2009 |
| Drug |
pyridoxine |
1 |
2013 |
| Drug |
pyroxamide |
1 |
2002 |
| Drug |
pz01 car-t cells |
1 |
2017 |
| Drug |
qol questionnaire, peg-filgrastim |
1 |
2008 |
| Drug |
qs-21 (stimulation-qs-21) drug |
1 |
1999 |
| Other |
quality of life measurements |
1 |
2018 |
| Procedure |
quantitative t-, b-, |
1 |
2009 |
| Procedure |
quantitative t-, b-,/nk cell subsets |
1 |
2009 |
| Other |
questionnaires/scales |
1 |
2017 |
| Drug |
quisinostat, 12 mg |
1 |
2011 |
| Drug |
r-(-)-gossypol acetic acid |
1 |
2009 |
| Drug |
r-acvbp14 induction regimen |
1 |
2007 |
| Drug |
r-bendamustine |
1 |
2013 |
| Drug |
r-bl-m-04 |
1 |
2018 |
| Drug |
r-bl-m-04 / auto-sct |
1 |
2018 |
| Drug |
r-cdop |
1 |
2015 |
| Drug |
r-cdop/cdope/dbvd chemotherapy regimen |
1 |
2015 |
| Combination Product |
r-choep |
1 |
2017 |
| Drug |
r-choep chemotherapy |
1 |
2017 |
| Drug |
r-choep14x6 |
1 |
2011 |
| Drug |
r-choep14x6/hd-arac/hd-mtx |
1 |
2011 |
| Other |
r-chop-14r-hidac,followed by rit |
1 |
2011 |
| Other |
r-chop-14r-hidac,followed by rit/hdt/ascr. |
1 |
2011 |
| Drug |
r-chop / acalabrutinib |
1 |
2017 |
| Other |
r-chop / placebo |
1 |
2017 |
| Drug |
r-chop / r-had |
1 |
2013 |
| Drug |
r-chop/chope/abvd chemotherapy regimen |
1 |
2015 |
| Drug |
r-chop/gm-csf |
1 |
2007 |
| Drug |
r-chop/r-bendamustine |
1 |
2013 |
| Drug |
r-chop/r-dhap |
1 |
2016 |
| Drug |
r-chop14 induction regimen |
1 |
2007 |
| Drug |
r-combination chemotherapy |
1 |
2019 |
| Drug |
r-dha |
1 |
2011 |
| Drug |
r-dhap/r-ice |
1 |
2015 |
| Drug |
r-epoch |
1 |
2008 |
| Drug |
r-epoch/cart |
1 |
2008 |
| Drug |
r-fc |
1 |
2011 |
| Procedure |
r-fcm |
1 |
2006 |
| Drug |
r-gemox |
1 |
2012 |
| Drug |
r-had |
1 |
2013 |
| Drug |
r-megachop |
1 |
2008 |
| Drug |
r-mnhl-bfm-90 |
1 |
2016 |
| Drug |
r-mnhl-bfm-90 / auto-sct |
1 |
2016 |
| Drug |
r mini chop |
1 |
2009 |
| Biological |
r/cvp/ifn |
1 |
2009 |
| Drug |
r2-combination chemotherapy |
1 |
2019 |
| Biological |
rabbit anti-thymocyte globulin (atg) |
1 |
2007 |
| Device |
rabbit antithymocyte globulin |
1 |
2018 |
| Drug |
rad001 (everolimus) |
1 |
2010 |
| Radiation |
radiation therapy (rt) |
1 |
2000 |
| Drug |
radiolabeled epratuzumab |
1 |
2003 |
| Biological |
radiolabeled monoclonal antibody anti-b1 for the treatment of b-cell lymphomas (tositumomab |
1 |
2012 |
| Biological |
radiolabeled monoclonal antibody anti-b1 for the treatment of b-cell lymphomas (tositumomab/iodine i 131 tositumomab) |
1 |
2012 |
| Procedure |
radionuclide imaging |
1 |
2007 |
| Radiation |
radiotherapy (rt) |
1 |
2018 |
| Radiation |
radiotherapy consolidation |
1 |
2009 |
| Other |
radiotherapy followed by chemotherapy |
1 |
2015 |
| Biological |
radiotherapy, rituximab |
1 |
2013 |
| Biological |
radiotherapy, rituximab/dc |
1 |
2013 |
| Radiation |
radiotherapy: |
1 |
2016 |
| Drug |
raltegravir |
1 |
2009 |
| Drug |
ramucirumab |
1 |
2016 |
| Drug |
ramucirumab / paclitaxel |
1 |
2016 |
| Drug |
rasburicase sr29142 |
1 |
2020 |
| Drug |
ravuconazole |
1 |
2003 |
| Drug |
rchop |
1 |
2013 |
| Drug |
rcomp |
1 |
2013 |
| Device |
reagent system |
1 |
2014 |
| Biological |
recombinant flt3 ligand |
1 |
2000 |
| Drug |
recombinant human interleukin 21 |
1 |
2006 |
| Drug |
recombinant human interleukin 21/rituximab |
1 |
2006 |
| Biological |
recombinant human thrombopoietin |
1 |
2000 |
| Drug |
recombinant humanized monoclonal antibody mil62 injection |
1 |
2019 |
| Biological |
recombinant interferon alpha-1b |
1 |
2006 |
| Biological |
recombinant interleukin-11 |
1 |
1999 |
| Biological |
recombinant interleukin-3 |
1 |
2000 |
| Drug |
reduced intensity conditioning |
1 |
2014 |
| Procedure |
reduced intensity conditioning with allogeneic transplant |
1 |
2005 |
| Procedure |
reduced intensity haplodentical stem cell transplant |
1 |
2012 |
| Drug |
reduced_intensity conditioning |
1 |
2010 |
| Biological |
refractory low-grade |
1 |
2012 |
| Drug |
regimen a |
1 |
2006 |
| Drug |
regimen b |
1 |
2006 |
| Drug |
regn1979 multiple dose levels |
1 |
2014 |
| Drug |
reinduction |
1 |
2015 |
| Biological |
related |
1 |
2016 |
| Biological |
related/unrelated bone marrow cells |
1 |
2016 |
| Behavioral |
relaxation |
1 |
2014 |
| Drug |
repaglinide |
1 |
2016 |
| Drug |
resminostat (4sc-201) |
1 |
2009 |
| Genetic |
reverse transcriptase-polymerase chain reaction |
1 |
2008 |
| Drug |
revlimid |
1 |
2018 |
| Drug |
revlimid (lenalidomide) |
1 |
2017 |
| Drug |
rft5-smpt-dga |
1 |
2001 |
| Drug |
rgx-104 |
1 |
2016 |
| Drug |
rhg-csf |
1 |
2019 |
| Drug |
rhil-15 |
1 |
2019 |
| Drug |
rhuflt3l |
1 |
2013 |
| Drug |
rhuflt3l/cdx-301 |
1 |
2013 |
| Drug |
rhuph20 |
1 |
2019 |
| Drug |
ribavirin |
1 |
2018 |
| Drug |
ribvd |
1 |
2011 |
| Drug |
ric |
1 |
2019 |
| Drug |
rice |
1 |
2017 |
| Drug |
ricover-scheme rituximab |
1 |
2011 |
| Drug |
ridaforolimus |
1 |
2010 |
| Drug |
rifampicin |
1 |
2013 |
| Drug |
ritiximab |
1 |
2009 |
| Drug |
rituxanâ„¢ |
1 |
2007 |
| Drug |
rituximab-bendamustine |
1 |
2011 |
| Drug |
rituximab-coated nanoparticle ar160 |
1 |
2016 |
| Drug |
rituximab-cvp |
1 |
2011 |
| Drug |
rituximab-dexamethasone-lenalidomide |
1 |
2016 |
| Drug |
rituximab-hds |
1 |
2006 |
| Drug |
rituximab - bendamustine |
1 |
2012 |
| Drug |
rituximab - chop |
1 |
2012 |
| Drug |
rituximab - cvp |
1 |
2012 |
| Drug |
rituximab -chop |
1 |
2005 |
| Drug |
rituximab -chop/velcade |
1 |
2005 |
| Drug |
rituximab (iv) |
1 |
2014 |
| Drug |
rituximab (mabtheraâ®, roche pty ltd, basel, switzerland) |
1 |
2011 |
| Drug |
rituximab (r-gemox) |
1 |
2005 |
| Drug |
rituximab (rituxan) |
1 |
2008 |
| Drug |
rituximab (rtx) |
1 |
2016 |
| Drug |
rituximab / acvbp regimen/pegfilgrastim |
1 |
2005 |
| Drug |
rituximab / bi-weekly chop |
1 |
2005 |
| Drug |
rituximab / chop chemotherapy |
1 |
2005 |
| Drug |
rituximab / dhap |
1 |
2009 |
| Drug |
rituximab / hd- methotrexate (mtx) |
1 |
2014 |
| Drug |
rituximab / idec-c2b8 |
1 |
2014 |
| Drug |
rituximab / mg4101 |
1 |
2018 |
| Drug |
rituximab / observation |
1 |
2009 |
| Drug |
rituximab / standard chop |
1 |
2005 |
| Drug |
rituximab 375 mg/m^2 |
1 |
2008 |
| Drug |
rituximab 375 mg/m2 |
1 |
2005 |
| Drug |
rituximab biosimilar |
1 |
2020 |
| Drug |
rituximab fludarabine cyclophosphamide |
1 |
2009 |
| Drug |
rituximab for patients with b-cell malignancies |
1 |
2006 |
| Drug |
rituximab i.v. |
1 |
2013 |
| Drug |
rituximab in combination with methotrexate, cytarabine |
1 |
2019 |
| Drug |
rituximab in combination with methotrexate, cytarabine/dexamethasone |
1 |
2019 |
| Drug |
rituximab maintenance |
1 |
2006 |
| Drug |
rituximab s.c. |
1 |
2013 |
| Drug |
rituximab window |
1 |
2017 |
| Drug |
rituximab, bendamustine |
1 |
2014 |
| Drug |
rituximab, bendamustine, cytarabine |
1 |
2009 |
| Drug |
rituximab, bendamustine, cytarabine. |
1 |
2012 |
| Drug |
rituximab, bendamustine, mitoxantrone, dexamethasone |
1 |
2010 |
| Drug |
rituximab, cmc544, gemcitabine |
1 |
2012 |
| Drug |
rituximab, cmc544, gemcitabine/oxaliplatine |
1 |
2012 |
| Drug |
rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone, liposomal cytarabine, methotrexate |
1 |
2009 |
| Drug |
rituximab, cyclophosphamide, etoposide, prednisone, vorinostat |
1 |
2008 |
| Drug |
rituximab, cyclophosphamide, etoposide, prednisone, vorinostat/qol questionnaire, peg-filgrastim/filgrastim |
1 |
2008 |
| Drug |
rituximab, cyclophosphamide, vincristine, |
1 |
2011 |
| Drug |
rituximab, cyclophosphamide, vincristine,/prednisolone |
1 |
2011 |
| Drug |
rituximab, gemcitabine, oxaliplatin |
1 |
2012 |
| Drug |
rituximab, gemcitabine, oxaliplatin, dexametasone |
1 |
2011 |
| Drug |
rituximab, ifosfamide, carboplatin, vp-16, mesna, g-csf, stem cell transplant |
1 |
2007 |
| Drug |
rituximab, ifosfamide, etoposide, carboplatin |
1 |
2008 |
| Drug |
rituximab, ifosfamide, etoposide, carboplatin, stem cell collection, mitoxantrone, cyclophosphamide |
1 |
2008 |
| Drug |
rituximab, ifosfamide, etoposide, carboplatin, stem cell collection, mitoxantrone, cyclophosphamide/etoposide, carmustine |
1 |
2008 |
| Drug |
rituximab, methotrexate, temozolomide |
1 |
2014 |
| Other |
rituximab, methotrexate, vincristine, procarbazine, pbpcs collection, busulfan, thiotepa, |
1 |
2008 |
| Other |
rituximab, methotrexate, vincristine, procarbazine, pbpcs collection, busulfan, thiotepa,/cyclophosphamide |
1 |
2008 |
| Drug |
rituximab, mitoxantrone, bendamustine |
1 |
2011 |
| Drug |
rituximab, vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-c |
1 |
2012 |
| Drug |
rituximab,fludarabine, cyclophosphamide |
1 |
2006 |
| Drug |
rituximab/bendamustine |
1 |
2009 |
| Drug |
rituximab/chlorambucil |
1 |
2005 |
| Drug |
rituximab/chop |
1 |
2018 |
| Other |
rituximab/chop regimen / pbsct |
1 |
2010 |
| Drug |
rituximab/dexabeam |
1 |
2014 |
| Drug |
rituximab/lenalidomide |
1 |
2012 |
| Drug |
rituximab/with eshap |
1 |
2007 |
| Drug |
rituxumab |
1 |
2018 |
| Drug |
ro-choep-21 (phase i) |
1 |
2014 |
| Drug |
ro-choep-21 (phase ii) |
1 |
2014 |
| Drug |
ro6870810 |
1 |
2017 |
| Drug |
ro7227166 |
1 |
2019 |
| Drug |
roflumilast |
1 |
2018 |
| Drug |
romidepsin (depsipeptide, fk228) |
1 |
2005 |
| Drug |
romidepsin / chop |
1 |
2013 |
| Drug |
romidepsin / gemcitabine |
1 |
2013 |
| Drug |
romidepsin/chop |
1 |
2011 |
| Drug |
rosiglitazone |
1 |
2005 |
| Drug |
rosiglitazone/bexarotene |
1 |
2005 |
| Biological |
rtxm83 |
1 |
2014 |
| Drug |
s 55746 |
1 |
2016 |
| Drug |
s65487 |
1 |
2018 |
| Biological |
sait101 |
1 |
2016 |
| Dietary Supplement |
salvia hispanica seed |
1 |
2016 |
| Drug |
sapanisertib |
1 |
2015 |
| Biological |
sargramostim (gm-csf) |
1 |
2006 |
| Drug |
sb-485232 |
1 |
2004 |
| Drug |
sb-743921 |
1 |
2006 |
| Drug |
sc-peg |
1 |
2012 |
| Other |
scales |
1 |
2017 |
| Biological |
scri-hucar19v1 |
1 |
2018 |
| Procedure |
sct |
1 |
2012 |
| Biological |
sct-i10a |
1 |
2019 |
| Drug |
sdx-105 |
1 |
2003 |
| Drug |
second-line ibrutinib |
1 |
2012 |
| Biological |
selected autologous stem cell infusion |
1 |
2014 |
| Biological |
selected natural killer cells collected from apheresis products |
1 |
2011 |
| Radiation |
selective external radiation therapy |
1 |
2011 |
| Drug |
selicrelumab |
1 |
2019 |
| Drug |
selpercatinib |
1 |
2017 |
| Drug |
selumetinib sulfate |
1 |
2017 |
| Device |
sentinel |
1 |
2017 |
| Drug |
sgn-30 |
1 |
2004 |
| Drug |
sgn-30 (anti-cd30 mab) |
1 |
2004 |
| Drug |
sgn-30 (monoclonal antibody) |
1 |
2003 |
| Drug |
sgn-40 (anti-hucd40 mab) |
1 |
2005 |
| Drug |
sgn-75 |
1 |
2009 |
| Drug |
sgn-cd70a |
1 |
2014 |
| Drug |
sgn-tgt |
1 |
2020 |
| Drug |
sgx301 (synthetic hypericin) |
1 |
2015 |
| Procedure |
sham intervention |
1 |
2002 |
| Drug |
shape (shp-141) 0.1% bid |
1 |
2011 |
| Drug |
shape (shp-141) 0.5% bid |
1 |
2011 |
| Drug |
shape (shp-141) 1.0% bid |
1 |
2011 |
| Drug |
shc014748m |
1 |
2018 |
| Drug |
shr2554 |
1 |
2018 |
| Biological |
single dose of cnct19 |
1 |
2020 |
| Drug |
sintilimab,pegaspargase,gemcitabine,oxaliplatin |
1 |
2019 |
| Biological |
siplizumab |
1 |
2011 |
| Drug |
sirolimus (sir) |
1 |
2017 |
| Drug |
sirolimus/methotrexate |
1 |
2010 |
| Drug |
sl-279252 |
1 |
2019 |
| Other |
smartcare |
1 |
2019 |
| Drug |
sns-062 |
1 |
2017 |
| Drug |
snx-5422 |
1 |
2008 |
| Drug |
snx-5422 mesylate hsp90 inhibitor |
1 |
2008 |
| Procedure |
socio-aesthetic care |
1 |
2014 |
| Drug |
sodium ferric gluconate complex in sucrose |
1 |
2008 |
| Drug |
sodium thiosulfate |
1 |
2006 |
| Drug |
sofosbuvir |
1 |
2016 |
| Drug |
sofosbuvir/velpatasvir |
1 |
2016 |
| Drug |
soluble beta-glucan (sbg) |
1 |
2007 |
| Drug |
soludomerin |
1 |
2014 |
| Drug |
solumedrol |
1 |
2009 |
| Drug |
spartalizumab |
1 |
2020 |
| Procedure |
special studies |
1 |
2009 |
| Diagnostic Test |
spect with 99mtc-1-thio-d-glucose |
1 |
2020 |
| Drug |
spleen tyrosine kinase inhibitor tak-659 |
1 |
2018 |
| Other |
sport therapy |
1 |
2019 |
| Drug |
src kinase inhibitor kx2-391 |
1 |
2008 |
| Dietary Supplement |
st. john’s wort |
1 |
2000 |
| Radiation |
standard arm |
1 |
2016 |
| Drug |
standard chemotherapy |
1 |
2005 |
| Drug |
standard chemotherapy chop |
1 |
2009 |
| Drug |
standard chemotherapy chop / ritiximab |
1 |
2009 |
| Drug |
standard chop |
1 |
2005 |
| Drug |
standard gvhd prophylaxis |
1 |
2005 |
| Drug |
standard induction chemotherapy |
1 |
2007 |
| Drug |
standard maintenance |
1 |
2013 |
| Diagnostic Test |
standard mri |
1 |
2017 |
| Other |
standard of care systemic therapy |
1 |
2019 |
| Radiation |
standard subtotal nodal irradiation |
1 |
1999 |
| Drug |
stanford v chemotherapy |
1 |
2009 |
| Drug |
stanford v regimen |
1 |
1999 |
| Procedure |
stem cell collection |
1 |
2011 |
| Procedure |
stem cell mobilization |
1 |
2018 |
| Procedure |
stem cell mobilization/collection |
1 |
2018 |
| Procedure |
stem cell source |
1 |
2005 |
| Procedure |
stem cell transfusion |
1 |
2003 |
| Genetic |
stem cell transplant (stc) |
1 |
2011 |
| Procedure |
stem cell transplant, |
1 |
2005 |
| Biological |
streptococcus pneumoniae |
1 |
2007 |
| Drug |
stro-001 |
1 |
2018 |
| Other |
structured education dvd |
1 |
2015 |
| Other |
structured education dvd / verbal teaching |
1 |
2015 |
| Other |
study of socioeconomic |
1 |
2008 |
| Other |
study of socioeconomic/demographic variables |
1 |
2008 |
| Drug |
subcutaneous (sc) sea-cd40 |
1 |
2015 |
| Drug |
sunitinib |
1 |
2008 |
| Drug |
supersaturated calcium phosphate rinse |
1 |
2011 |
| Drug |
support treatment |
1 |
2007 |
| Other |
survival |
1 |
2015 |
| Drug |
syb l-0501ri |
1 |
2019 |
| Drug |
sym021 |
1 |
2017 |
| Drug |
synb1891 |
1 |
2019 |
| Biological |
syngeneic pbtls |
1 |
2008 |
| Drug |
systematic chemotherapy |
1 |
2005 |
| Drug |
systematic chemotherapy/antibodies |
1 |
2005 |
| Combination Product |
systemic therapy |
1 |
2019 |
| Biological |
t-allo10 |
1 |
2017 |
| Genetic |
t-cell infusion |
1 |
2011 |
| Biological |
t-lymphocytes |
1 |
2017 |
| Biological |
t cell-depleted donor lymphocyte infusion |
1 |
2015 |
| Biological |
t cell-depleted hematopoietic stem cell transplantation |
1 |
2016 |
| Biological |
taa-t cells |
1 |
2019 |
| Drug |
tacrolimus (arm with methotrexate) |
1 |
2014 |
| Drug |
tacrolimus (arm with mmf |
1 |
2014 |
| Drug |
tacrolimus (arm with mmf/cyclophosphamide) |
1 |
2014 |
| Drug |
tacrolimus (tac) |
1 |
2018 |
| Drug |
tacrolimus 120 |
1 |
2011 |
| Drug |
tacrolimus 60 |
1 |
2011 |
| Drug |
tacrolimus 90 |
1 |
2011 |
| Drug |
tafasitamab/lenalidomide |
1 |
2019 |
| Drug |
tak-901 |
1 |
2009 |
| Drug |
tak-981 |
1 |
2019 |
| Biological |
talimogene laherparepvec |
1 |
2016 |
| Procedure |
tandem high-dose therapy (hdt) followed by autologous peripheral blood stem cell (pbsc) |
1 |
2009 |
| Other |
taped music |
1 |
2013 |
| Biological |
tar decoy-transduced autologous cd34-positive hematopoietic progenitor cells |
1 |
2016 |
| Drug |
targretinâ® (bexarotene) |
1 |
2005 |
| Drug |
taxane (cytotoxic, bay59-8862) |
1 |
2002 |
| Drug |
tazemetostat/[14c] tazemetostat |
1 |
2016 |
| Drug |
tazobactam sodium |
1 |
1999 |
| Drug |
tbo-filgrastim |
1 |
2017 |
| Drug |
tc-110 t cells |
1 |
2020 |
| Biological |
tcrî± |
1 |
2019 |
| Biological |
tcrî±/î²/ |
1 |
2019 |
| Procedure |
tcrî±î² |
1 |
2015 |
| Procedure |
tcrî±î²//cd19/ depleted haploidentical hsct |
1 |
2015 |
| Drug |
tedd |
1 |
2014 |
| Drug |
tedd-r |
1 |
2019 |
| Drug |
teddi |
1 |
2014 |
| Drug |
teddi-r |
1 |
2019 |
| Behavioral |
telephone-based intervention |
1 |
2009 |
| Behavioral |
telephone counselling |
1 |
2017 |
| Biological |
tem1 monoclonal antibody morab-004 |
1 |
2012 |
| Drug |
temozolomide 100 mg |
1 |
2003 |
| Drug |
temozolomide 100 mg/m^2 |
1 |
2003 |
| Drug |
temozolomide 150 mg |
1 |
2003 |
| Drug |
temozolomide 150 mg/m^2 |
1 |
2003 |
| Drug |
temozolomide 200 mg |
1 |
2003 |
| Drug |
temozolomide 200 mg/m^2 |
1 |
2003 |
| Drug |
temsirolimus (cci-779) |
1 |
2005 |
| Drug |
temsirolimus, rituximab, bendamustin |
1 |
2010 |
| Drug |
tenalisib |
1 |
2018 |
| Drug |
tenalisib, |
1 |
2018 |
| Drug |
tenofovir disoproxil |
1 |
2014 |
| Procedure |
tep au mibi |
1 |
2007 |
| Biological |
tetanus |
1 |
2012 |
| Biological |
tetanus-cmv fusion peptide vaccine |
1 |
2012 |
| Biological |
tetanus toxoid |
1 |
2015 |
| Drug |
tetrahydrouridine |
1 |
2016 |
| Drug |
tg-0054 (2.24 mg |
1 |
2009 |
| Drug |
tg-0054 (2.24 mg/kg) |
1 |
2009 |
| Drug |
tg-0054 (3.14 mg |
1 |
2009 |
| Drug |
tg-0054 (3.14 mg/kg) |
1 |
2009 |
| Drug |
tg-0054/with g-csf |
1 |
2014 |
| Drug |
tg-1501 |
1 |
2018 |
| Drug |
tg-1801 |
1 |
2019 |
| Drug |
tg02 citrate |
1 |
2012 |
| Biological |
tgfbeta resistant lmp-specific ctls |
1 |
2006 |
| Drug |
tgr-1202 / brentuximab vedotin |
1 |
2014 |
| Drug |
tgr-1202 / ublituximab / bendamustine |
1 |
2016 |
| Drug |
thalidomide, pharmion |
1 |
2006 |
| Drug |
thalidomide/with r-chop |
1 |
2017 |
| Drug |
therapeutic entecavir |
1 |
2009 |
| Biological |
therapeutic immune globulin |
1 |
2008 |
| Drug |
thioguanine (oral) |
1 |
2016 |
| Drug |
thioplexâ® |
1 |
2007 |
| Drug |
tinostamustine |
1 |
2015 |
| Drug |
tinzaparin |
1 |
2014 |
| Drug |
tiragolumab |
1 |
2019 |
| Drug |
tisagenlecleucel after optional bridging |
1 |
2018 |
| Drug |
tisagenlecleucel after optional bridging/lymphodepleting chemotherapy |
1 |
2018 |
| Drug |
tislelizumab (bgb-a317) |
1 |
2017 |
| Other |
titrated pain management |
1 |
2008 |
| Drug |
tj011133 |
1 |
2019 |
| Procedure |
tli |
1 |
2009 |
| Drug |
topical resiquimod 0.03% |
1 |
2012 |
| Drug |
topical resiquimod 0.06% |
1 |
2012 |
| Drug |
torisel 75 mg |
1 |
2011 |
| Drug |
torisel 75 mg/r-dha |
1 |
2011 |
| Drug |
torisel dose 15 mg |
1 |
2011 |
| Drug |
torisel dose 15 mg/r-chop |
1 |
2011 |
| Drug |
torisel dose 15 mg/r-dha |
1 |
2011 |
| Drug |
torisel dose 15 mg/r-fc |
1 |
2011 |
| Drug |
torisel dose 25 mg |
1 |
2011 |
| Drug |
torisel dose 25 mg/r-chop |
1 |
2011 |
| Drug |
torisel dose 25 mg/r-dha |
1 |
2011 |
| Drug |
torisel dose 25 mg/r-fc |
1 |
2011 |
| Drug |
torisel dose 50 mg |
1 |
2011 |
| Drug |
torisel dose 50 mg/r-chop |
1 |
2011 |
| Drug |
torisel dose 50 mg/r-dha |
1 |
2011 |
| Drug |
torisel dose 50 mg/r-fc |
1 |
2011 |
| Drug |
torisel dose 75 mg |
1 |
2011 |
| Drug |
torisel dose 75 mg/r-chop |
1 |
2011 |
| Drug |
torisel dose 75 mg/r-fc |
1 |
2011 |
| Biological |
tositumomab (anti-b1 antibody) |
1 |
2010 |
| Biological |
tositumomab (anti-b1 antibody)/iodine-131 tositumomab |
1 |
2010 |
| Drug |
tositumomab 35 mg |
1 |
2005 |
| Drug |
tositumomab 450 mg |
1 |
2005 |
| Drug |
tositumomab i-131 |
1 |
2007 |
| Drug |
tositumomab/iodine i-131 tositumomab |
1 |
2013 |
| Biological |
tositumomab/iodine i 131 tositumomab (anti-b1 antibody) |
1 |
2009 |
| Biological |
tositumomab/iodine i 131 tositumomab (anti-b1 antibody/iodine-131 anti-b1 antibody) |
1 |
2009 |
| Biological |
tositumomab/iodine i 131 tositumomab followed by chop |
1 |
2009 |
| Radiation |
total-body irradiation (tbi) |
1 |
2007 |
| Procedure |
total body irradiation (8gy |
1 |
2006 |
| Procedure |
total body irradiation (8gy/4fr) |
1 |
2006 |
| Radiation |
total body irradiation (tbi) 200cgy on day -1 |
1 |
2016 |
| Radiation |
total body irradiation (tbi) 200cgy twice a day on days -3, -2, -1 |
1 |
2016 |
| Radiation |
total body radiation |
1 |
2011 |
| Radiation |
total body radiation (tbi) |
1 |
2007 |
| Radiation |
total lymphoid irradiation (tli) |
1 |
2018 |
| Radiation |
total marrow irradiation |
1 |
2014 |
| Drug |
tq-b3101 capsule |
1 |
2020 |
| Drug |
tqb2303 |
1 |
2018 |
| Drug |
tqb2450 |
1 |
2019 |
| Drug |
trail-r1 mab (trm-1; hgs-etr1) |
1 |
2004 |
| Drug |
trametinib |
1 |
2015 |
| Biological |
transformed low-grade non-hodgkin’s lymphoma (nhl) |
1 |
2012 |
| Procedure |
transplantation |
1 |
2006 |
| Drug |
traumeel s |
1 |
2004 |
| Drug |
trc 102 |
1 |
2013 |
| Drug |
treatment plan |
1 |
2017 |
| Biological |
treg infusion |
1 |
2008 |
| Drug |
tremelimumab |
1 |
2015 |
| Drug |
tretinoin |
1 |
1999 |
| Drug |
triamcinolone |
1 |
2017 |
| Drug |
triapine |
1 |
2006 |
| Biological |
tricar-t-cd19 |
1 |
2018 |
| Biological |
trim5alpha |
1 |
2016 |
| Drug |
trimetrexate glucuronate |
1 |
1999 |
| Drug |
tripegfilgrastim |
1 |
2016 |
| Biological |
trivalent inactivated influenza vaccine |
1 |
2006 |
| Biological |
trivalent influenza vaccine |
1 |
2015 |
| Drug |
trph-222 |
1 |
2018 |
| Biological |
trq15-01 |
1 |
2019 |
| Drug |
tru-016 |
1 |
2011 |
| Drug |
tru-016 (anti-cd37 protein therapeutic) |
1 |
2008 |
| Biological |
tru-016 10-20 mg |
1 |
2012 |
| Biological |
tru-016 10-20 mg/kg / bendamustine |
1 |
2012 |
| Biological |
tru-016 10-20 mg/kg / ibrutinib |
1 |
2012 |
| Biological |
tru-016 20 mg |
1 |
2012 |
| Biological |
tru-016 20 mg/kg / obinutuzumab |
1 |
2012 |
| Biological |
tru-016 6-20 mg |
1 |
2012 |
| Biological |
tru-016 6-20 mg/kg / idelalisib / rituximab |
1 |
2012 |
| Biological |
tsebt |
1 |
2015 |
| Drug |
tsr-011 |
1 |
2014 |
| Biological |
ttf-ngr |
1 |
2016 |
| Drug |
tti-622 |
1 |
2018 |
| Drug |
tti-622 / pd-1 inhibitor |
1 |
2018 |
| Drug |
tti-622 / proteasome-inhibitor regimen |
1 |
2018 |
| Drug |
tti-622 / rituximab |
1 |
2018 |
| Drug |
tti-622 monotherapy |
1 |
2018 |
| Drug |
ttx-030 |
1 |
2019 |
| Biological |
tumor-pulsed dendritic cells |
1 |
2000 |
| Drug |
txa127 |
1 |
2010 |
| Drug |
txa127 1000 mcg |
1 |
2011 |
| Drug |
txa127 1000 mcg/kg/day |
1 |
2011 |
| Drug |
txa127 300 mcg |
1 |
2011 |
| Drug |
txa127 300 mcg/kg/day |
1 |
2011 |
| Biological |
ucart019 |
1 |
2017 |
| Biological |
ucd19 car t cells |
1 |
2020 |
| Genetic |
umbilical cord blood (ucb) |
1 |
2013 |
| Biological |
umbilical cord blood cell infusion |
1 |
2016 |
| Biological |
universal dual specificity cd19 |
1 |
2018 |
| Biological |
universal dual specificity cd19/cd20/cd22 car-t cells |
1 |
2018 |
| Biological |
unrelated bone marrow cells |
1 |
2016 |
| Drug |
urelumab (bms-663513) |
1 |
2011 |
| Procedure |
uv light therapy |
1 |
2003 |
| Procedure |
vaccine-primed t-cells |
1 |
2007 |
| Drug |
valchlor 0.016 % topical gel |
1 |
2017 |
| Drug |
valemetostat tosylate |
1 |
2019 |
| Drug |
valganciclovir |
1 |
2005 |
| Drug |
valproate |
1 |
2012 |
| Drug |
valsartan |
1 |
2005 |
| Drug |
vancomycin |
1 |
1999 |
| Drug |
vandetanib |
1 |
2008 |
| Drug |
vcap |
1 |
2010 |
| Drug |
vcap-amp-vecp with g-csf |
1 |
2005 |
| Drug |
vcap-amp-vecp with g-csf/intrathecal prophylaxis |
1 |
2005 |
| Drug |
vcap/amp/vecp(mlsg15) |
1 |
2010 |
| Biological |
vcl-cb01 |
1 |
2006 |
| Drug |
vcr |
1 |
2014 |
| Drug |
vecp(mlsg15) |
1 |
2010 |
| Drug |
velcade (ps-341, bortezomib) |
1 |
2010 |
| Drug |
velcade 1.3 mg |
1 |
2008 |
| Drug |
velcade 1.3 mg/m^2 |
1 |
2008 |
| Drug |
velcade tm (bortezomib) for injection |
1 |
2003 |
| Drug |
velcade/rituximab |
1 |
2004 |
| Drug |
velpatasvir |
1 |
2016 |
| Biological |
veltuzumab/milatuzumab |
1 |
2009 |
| Drug |
ven (venetoclax) |
1 |
2017 |
| Drug |
verapamil |
1 |
2017 |
| Drug |
verapamil hydrochloride |
1 |
2017 |
| Other |
verbal teaching |
1 |
2015 |
| Drug |
vidaza |
1 |
2014 |
| Drug |
vinblastin |
1 |
2018 |
| Drug |
vincristin |
1 |
2007 |
| Drug |
vincristine 1.4 mg |
1 |
2008 |
| Drug |
vincristine 1.4 mg/m^2 |
1 |
2008 |
| placebo |
vincristine placebo |
1 |
2017 |
| Drug |
vincristine sulfate liposome injection/rituximab |
1 |
2013 |
| Drug |
vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-c |
1 |
2012 |
| Drug |
vincristine/vindesine |
1 |
2005 |
| Drug |
vindesine sulfate |
1 |
2017 |
| Drug |
vinorelbine tartrate / g-csf |
1 |
2006 |
| Drug |
vinorelbine, oxalplatin, ifosfasmide, etoposide, mitoxatrone, gemcitabine |
1 |
2004 |
| Drug |
vinorelbine, oxalplatin, ifosfasmide, etoposide, mitoxatrone, gemcitabine/rituximab |
1 |
2004 |
| Drug |
vip |
1 |
2009 |
| Drug |
vip/abvd |
1 |
2009 |
| Biological |
visilizumab |
1 |
2000 |
| Drug |
vismodegib |
1 |
2015 |
| Dietary Supplement |
vitamin b12/folic acid |
1 |
2016 |
| Dietary Supplement |
vitamin c |
1 |
2018 |
| Drug |
vli |
1 |
2006 |
| Drug |
vls-101 schedule 1 |
1 |
2019 |
| Drug |
vls-101 schedule 2 |
1 |
2019 |
| Drug |
vls-101 schedule 3 |
1 |
2019 |
| Drug |
vmd-928 300-mg capsules |
1 |
2018 |
| Drug |
voraxaze |
1 |
2018 |
| Drug |
voriconazole |
1 |
2003 |
| Drug |
vorinostat (saha) |
1 |
2010 |
| Drug |
voruciclib |
1 |
2018 |
| Drug |
vp-16 |
1 |
2012 |
| Other |
vp-16, cisplatin, ifosfamide, dexamethosone, mesna, if-rt |
1 |
2006 |
| Drug |
vp -16 |
1 |
2012 |
| Biological |
vt-ebv-n |
1 |
2018 |
| Drug |
vtp195183 |
1 |
2005 |
| Drug |
vtx-2337 |
1 |
2008 |
| Other |
wait |
1 |
2009 |
| Drug |
warfarin |
1 |
2011 |
| Other |
watch |
1 |
2009 |
| Other |
watch/wait |
1 |
2009 |
| Other |
watchful waiting |
1 |
2010 |
| Drug |
weight-based plerixafor |
1 |
2010 |
| Genetic |
welgenaleucel |
1 |
2019 |
| Radiation |
whole-brain radiation therapy |
1 |
2011 |
| Radiation |
whole brain radiotherapy |
1 |
2014 |
| Drug |
with alemtuzumab |
1 |
2008 |
| Drug |
with cmab304 |
1 |
2011 |
| Drug |
with eshap |
1 |
2007 |
| Drug |
with g-csf |
1 |
2014 |
| Drug |
with r-gdp |
1 |
2017 |
| Drug |
with sb-485232 |
1 |
2013 |
| Drug |
without copadm3 |
1 |
2005 |
| Drug |
without radiotherapy |
1 |
2008 |
| Drug |
without rituximab |
1 |
2019 |
| Drug |
wxfl10030390 |
1 |
2018 |
| Biological |
wztl002-1 (1928t2z car-t cells) |
1 |
2019 |
| Drug |
xl147 (sar245408) |
1 |
2007 |
| Drug |
xm02 filgrastim |
1 |
2014 |
| Biological |
xmab13676 |
1 |
2016 |
| Biological |
xmab2513 |
1 |
2008 |
| Genetic |
xyf19 car-t cell |
1 |
2019 |
| Biological |
y-90 humanized anti-tac |
1 |
1999 |
| Radiation |
y-90 ibritumomab |
1 |
2010 |
| Drug |
y-90 ibritumomab tiuxetan |
1 |
2007 |
| Drug |
y-zevalin |
1 |
2008 |
| Drug |
y zevalin |
1 |
2012 |
| Biological |
y90 ibritumomab tiuxetan rit |
1 |
2011 |
| Drug |
ym155 |
1 |
2009 |
| Biological |
yttrium-90 ibritumomab tiuxetan |
1 |
2003 |
| Drug |
yttrium-90 radiolabeled anti-tac antibody |
1 |
1999 |
| Drug |
yttrium-ibritumomab (zevalin) |
1 |
2002 |
| Radiation |
yttrium y 90-dota-biotin |
1 |
2015 |
| Radiation |
yttrium y 90-edotreotide |
1 |
2000 |
| Biological |
yttrium y 90-labeled basiliximab |
1 |
2011 |
| Biological |
yttrium y 90 basiliximab |
1 |
2015 |
| Radiation |
yttrium y 90 daclizumab |
1 |
2001 |
| Drug |
yy-20394 |
1 |
2020 |
| Drug |
zbeam (zevalin, bcnu, etoposide, aracytine, melphalan) |
1 |
2008 |
| Drug |
zevalin-bucye |
1 |
2006 |
| Biological |
zevalin ([90]y-ibritumomab tiuxetan, bay86-5128) |
1 |
2005 |
| Drug |
zevalin (ibritumomab tiuxetan) |
1 |
2009 |
| Drug |
zevalin (sh l 749 , bay86-5128) |
1 |
2005 |
| Drug |
zevalin radioimmunotherapy |
1 |
2002 |
| Drug |
zevalin/beam |
1 |
2005 |
| Drug |
zidovudine (azt) |
1 |
1999 |
| Drug |
zoledronate |
1 |
2015 |
| Drug |
zoledronic acid |
1 |
2006 |
| Drug |
zolinza |
1 |
2011 |
| Drug |
zolinza (vorinostat) |
1 |
2008 |
| Drug |
zolinza/vorinostat |
1 |
2011 |
| Drug |
zydelig |
1 |
2017 |